carbamates has been researched along with amprenavir in 433 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 89 (20.55) | 18.2507 |
| 2000's | 271 (62.59) | 29.6817 |
| 2010's | 67 (15.47) | 24.3611 |
| 2020's | 6 (1.39) | 2.80 |
| Authors | Studies |
|---|---|
| Livington, DJ; Painter, GR; Partaledis, JA; Pazhanisamy, S; Porter, DJ; Tung, RD | 1 |
| Blair, EE; Cullinan, AB; Falcione, C; Futer, O; Maschera, B; Myers, RE; Partaledis, JA; Pazhanisamy, S; Tisdale, M; Yamaguchi, K | 1 |
| Bilello, JA; Drusano, GL | 1 |
| Cullinan, AB; Livingston, DJ; Margolin, N; Pazhanisamy, S; Rao, BG; Stuver, CM | 1 |
| Blum, MR; Millard, J; Painter, G; Parry, N; Rooney, J; Sadler, BM; St Clair, MH; Tisdale, M | 1 |
| Chang, SY; Singh, R; Taylor, LC | 1 |
| Kim, EE; Murcko, MA; Rao, BG | 1 |
| Garsky, VM; Kuo, LC; Schock, HB | 1 |
| Blair, ED; Darby, G; Furfine, ES; Maschera, B; Myers, R; Palú, G; Tisdale, M; Wright, LL | 1 |
| Bold, G; Capraro, HG; Goutte, G; Klimkait, T; Lazdins, JK; Mestan, J; Walker, MR | 1 |
| Maggiora, GM; Mestres, J; Rohrer, DC | 1 |
| Miertus, S; Nair, AC; Romeo, D; Tossi, A | 1 |
| Livingston, DJ; Partaledis, JA; Pazhanisamy, S; Rao, BG | 1 |
| Itoh, E; Shibata, N; Terashima, S | 1 |
| Adkins, JC; Faulds, D | 1 |
| Bridson, GW; Chaturvedi, PR; Decker, CJ; Laitinen, LM; Raybuck, SA; Tung, RD | 1 |
| Bart, PA; Corpataux, JM; de Boer, RJ; Fleury, S; Gallant, S; Gillet, M; Glauser, MP; Graziosi, C; Knabenhans, C; Meuwly, JY; Meylan, P; Miedema, F; Otto, SA; Pantaleo, G; Rizzardi, GP; Schnyder, P; Soudeyns, H; Spreen, W; Welbon, CC; Wolthers, KC | 1 |
| Bilello, JA; Bilello, PA; Bye, A; D'Argenio, DZ; Drusano, GL; McDowell, J; Sadler, B; Symonds, W | 1 |
| Cammack, N; Chirn, GW; Craig, C; Dissanayeke, S; Duncan, IB; Gilbert, S; Moffatt, A; Race, E; Rose, J; Sheldon, J; Whittaker, L | 1 |
| Boden, D; Markowitz, M | 1 |
| Bawdon, RE | 1 |
| Caliendo, AM; Currier, JS; D'Aquila, RT; DeGruttola, V; Eron, JJ; Frank, I; Gerber, JG; Gulick, RM; Kuritzkes, DR; Murphy, RL; Smeaton, L; Sommadossi, JP; Tung, R | 1 |
| Cassano, P; Clumeck, N; De Wit, S; Gerard, M; Hermans, P; Kabeya, K; O'Doherty, E | 1 |
| Miller, SL | 1 |
| Chittick, GE; Hanson, CD; Roskell, NS; Sadler, BM; Symonds, WT | 1 |
| Baggett, TH; Gracia Jones, S | 1 |
| Bart, PA; Corpataux, JM; Fleury, S; Knabenhans, C; Meuwly, JY; Meylan, PR; Munoz, M; Pantaleo, G; Rizzardi, P; Welbon, C; Yerly, S | 1 |
| Brouwer, KR; Dennis, SW; Humphreys, JE; Jarrett, JL; Polli, JW; Studenberg, SD; Woolley, JL | 1 |
| Berger, J; Li, Z; MacNaul, K; Moller, DE; Szalkowski, D; Zhang, B | 1 |
| Temesgen, Z; Wright, AJ | 1 |
| Antunes, F; Brown, DJ; Clumeck, N; Fetter, A; Haubrich, R; Kahl, L; Lang, W; Pagano, G; Richman, D; Schooley, R; Sereni, D; Stein, A; Thompson, M; van der Ende, ME | 1 |
| Chittick, GE; Crouch, MA; Gouldin, W; Israel, DS; Lou, Y; Pastor, A; Polk, RE; Sadler, BM; Symonds, WT | 1 |
| Gatell, J | 1 |
| Bridgers, A; Coffin, M; Long, S; Polli, J; Roy, A; Vickers, A; Winnike, R; Yu, L | 1 |
| Falloon, J; Kavlick, MF; LaFon, S; Lane, HC; Manion, DJ; Masur, H; Mitsuya, H; Piscitelli, S; Rogers, M; Sadler, B; Vogel, S; Yoshimura, K | 1 |
| Anderson, C; Craik, CS; Jolly, DJ; Todd, S | 1 |
| Heinrikson, RL; Tomasselli, AG | 1 |
| Delvaux, M; Fosse, S; Gillotin, C; Lou, Y; Masliah, C; Petite, JP; Pillegand, B; Rautaureau, J; Sadler, BM; Stein, DS; Veronese, L | 1 |
| Brophy, DF; Chittick, GE; Gillotin, C; Israel, DS; Lou, Y; Pastor, A; Polk, RE; Sadler, BM; Symonds, WT | 1 |
| Bart, PA; Chapuis, A; De Boer, RJ; Fox, CH; Halkic, N; Hoover, S; Lange, JM; Lazzarin, A; Miller, V; Notermans, DW; Pantaleo, G; Perrin, L; Rizzardi, GP; Staszewski, S; Tambussi, G | 1 |
| Arnold, E; Das, K; Limoli, K; Parkin, NT; Petropoulos, CJ; Ziermann, R | 1 |
| Gulick, R | 1 |
| Currier, JS; D'Aquila, RT; Eron, JJ; Fiscus, SA; Gulick, RM; Lennox, JL; Murphy, RL; Rogers, MD; Smeaton, LM; Tung, R | 1 |
| Biollaz, J; Buclin, T; Decosterd, LA; Marzolini, C; Telenti, A | 1 |
| Barone, C; Bilello, JA; Bye, A; D'Argenio, DZ; Drusano, GL; LaFon, S; Preston, SL; Prince, W; Rogers, M; Symonds, W | 1 |
| Fung, HB; Hameed, R; Kirschenbaum, HL | 1 |
| Beijnen, JH; Hoetelmans, RM; Sparidans, RW | 1 |
| Daily, JP; Fahey, JM; Greenblatt, DJ; Perloff, MD; von Moltke, LL | 1 |
| Black, J; Markland, W; Parsons, JD; Rao, BG; Tisdale, M; Tung, R; Zuchowski, L | 1 |
| Jaillon, P; Poirier, JM; Radembino, N; Robidou, P | 1 |
| Condra, JH; Emini, EA; Petropoulos, CJ; Schleif, WA; Shivaprakash, M; Ziermann, R | 1 |
| Binley, JM; Clas, B; Hurley, A; Ketas, T; Little, S; Markowitz, M; Moore, JP; Richman, D; Schiller, D; Trkola, A | 1 |
| Duan, SX; Durol, AL; Greenblatt, DJ; von Moltke, LL | 1 |
| Croom, DK; Furfine, ES; Lenhard, JM; Reynolds, DJ; Spaltenstein, A; Weiel, JE | 1 |
| Biryahwaho, B; Dondero, T; Downing, R; Hu, DJ; Lal, R; Mastro, T; Nkengasong, J; Pieniazek, D; Rayfield, M; Soriano, V; Tanuri, A; Wiktor, SZ | 1 |
| Belohradsky, BH; Engelhorn, C; Hoffmann, F; Kurowski, M; Notheis, G; Wintergerst, U | 1 |
| Blanchard, SG; Furfine, ES; Ittoop, O; Jain, RG; Lenhard, JM; Orband-Miller, LA; Paulik, MA; Weiel, JE | 1 |
| Bart, PA; Chapuis, AG; Chave, JP; Corpataux, JM; Graziosi, C; Halkic, N; Lazzarin, A; McDade, H; Meuwly, JY; Meylan, P; Munoz, M; Pantaleo, G; Perrin, L; Rizzardi, GP; Spreen, W; Tambussi, G; Yerly, S | 1 |
| Duval, X; Farinotti, R; Lamotte, C; Le Moing, V; Leport, C; Longuet, C; Peytavin, G; Vildé, JL | 1 |
| Korn, K; Moschik, B; Paatz, C; Schmidt, B; Uberla, K; Walter, H | 1 |
| Conway, B; Shafran, SD | 1 |
| Tavel, JA | 1 |
| Brothers, CH; Feinberg, J; Fischl, M; Goodgame, JC; Hardy, WD; Jablonowski, H; Morrow, P; Nacci, P; Pedneault, L; Pottage, JC; Stein, A; Vafidis, I; Yeo, J | 1 |
| Bart, PA; Chapuis, AG; Lazzarin, A; Pantaleo, G; Rizzardi, GP; Tambussi, G | 1 |
| Gillotin, C; Lou, Y; Sadler, BM; Stein, DS | 2 |
| Koch, CA; Wolkersdoerfer, G | 1 |
| Aungst, BJ; Bulgarelli, JP; Nguyen, NH; Oates-Lenz, K | 1 |
| Goa, KL; Noble, S | 1 |
| Brophy, DF; Chittick, GE; Israel, DS; Kristoff, D; Lou, Y; Patron, R; Polk, RE; Sadler, BM; Stein, DS; Symonds, WT | 1 |
| Acosta, E; Currier, JS; D'Aquila, RT; Eron, JJ; Gerber, JG; Gulick, RM; Kuritzkes, DR; Murphy, RL; Smeaton, LM; Snyder, S; Sommadossi, JP; Tung, R | 1 |
| Carr, A; Cooper, DA; Cunningham, PH; Goh, LE; Grey, P; Kaufmann, GR; Smith, D; Suzuki, K; Zaunders, JJ | 1 |
| Brothers, C; Fetter, A; Millard, J; Pagano, G; Pedneault, L; Tymkewycz, P; Yeo, J | 1 |
| Ishizawa, M; Komatsu, H | 1 |
| Blom-Roosemalen, MC; Breimer, DD; de Boer, AG; Nabulsi, L; van der Sandt, IC; Voorwinden, HH; Vos, CM | 1 |
| Garrett, L; Garris, C; Graham, N; Pedneault, L; Rogers, M; Scott, T | 1 |
| Brouwer, KR; Huang, L; Polli, JW; Serabjit-Singh, C; Woolley, JL; Wring, SA | 1 |
| Chittick, GE; Kerkering, TM; Lou, Y; Moore, KH; Polk, RE; Sadler, BM; Slain, D; Stein, DS; Studenberg, SD; Woolley, JL | 1 |
| Caldwell, P; Furlan, S; Ho, D; Hurley, A; Johnson, J; Kost, RG; Markowitz, M; Smiley, L; Talal, A; Vesanen, M; Zhang, L | 1 |
| Brothers, CH; Scott, TR; Stein, AJ | 1 |
| Griswold, MP; Gunawan, S; Kahn, DG | 1 |
| Levin, J | 2 |
| Chang, HE | 1 |
| Coppedge, B | 1 |
| Baker, R; Bowers, M | 1 |
| Grinberg, L | 1 |
| Fakuda, D | 2 |
| Bartnof, HS | 1 |
| Gilden, D | 2 |
| Highleyman, L | 3 |
| Elwell, A | 1 |
| Prescott, LM | 1 |
| Gallant, JE | 1 |
| James, JS | 1 |
| Simmons, P | 1 |
| Fornataro, K; Jefferys, R | 1 |
| Arroyo, HT | 1 |
| Bartnoff, H; Deeks, S; Follansbee, S | 1 |
| Agosto, M | 1 |
| Eron, JJ; Haubrich, R; Lang, W; Millard, J; Pagano, G; Pedneault, L; Snowden, W; Tisdale, M; Wolfram, J | 1 |
| Iwamoto, A; Kotaki, H; Nakamura, T; Yamada, H | 1 |
| Lloyd, PP; Lou, Y; Piliero, PJ; Preston, SL; Sadler, BM; Stein, DS | 1 |
| Blanco, JL; Carné, X; Gatell, JM; López-Púa, Y; Mallolas, J; Sarasa-Nacenta, M | 1 |
| Arrizabalaga, J; Clotet, B; Martínez-Picado, J; Ruiz, L | 1 |
| Bartoli, A; Feroggio, M; Gianelli, L; Maserati, R; Montagna, M; Regazzi, MB; Villani, P | 1 |
| Bakshi, S; Black, K; Kodoth, S; Pahwa, S; Scimeca, P | 1 |
| Bourin, M; Dailly, E; Jolliet, P; Kergueris, MF; Thomas, L | 1 |
| Antunes, F; Blake, D; Clumeck, N; Danner, SA; Haubrich, R; Millard, J; Mustafa, N; Myers, RE; Nacci, P; Schooley, RT; Sereni, D; Thompson, M; Tisdale, M; van Der Ende, ME | 1 |
| Huff, B | 1 |
| Carter, LH; Danger, DP; Furfine, ES; Hanlon, MH; Porter, DJ | 1 |
| Bart, PA; Baumann, P; Eap, CB; Gallant, S; Golay, KP; Pantaleo, G; Rizzardi, PG | 1 |
| Gantke, B; Kuschak, D; Mauss, S; Schmutz, G | 1 |
| Mazzullo, JM; Piliero, PJ | 1 |
| Burger, D; Fätkenheuer, G; Kamps, R; Römer, K; Salzberger, B | 1 |
| D'Aquila, RT; Hanna, GJ; Zachary, KC | 1 |
| Atzori, C; Cargnel, A; Fantoni, G; Valerio, A | 1 |
| Eron, JJ; Gillotin, C; Haubrich, R; Lang, W; Lou, Y; Sadler, BM; Stein, DS | 1 |
| Pereira, A; Taylor, S | 1 |
| Gatell, JM | 1 |
| Gatanaga, H; Gorelick, RJ; Kavlick, MF; Mardy, S; Mitsuya, H; Nagashima, K; Summers, MF; Suzuki, Y; Tang, C; Tsang, H; Yoshimura, K | 1 |
| Clavel, F; Damond, F; Descamps, D; Duval, X; Lamotte, C; Leport, C; Peytavin, G; Race, E; Vilde, JL | 1 |
| Kuschak, D; Mauss, S; Schmutz, G | 1 |
| Sadler, BM; Stein, DS | 1 |
| Cohen, DM; James, CW; Matalia, MD; McNelis, KC; Szabo, S | 1 |
| Cohen, MS; Dunn, JA; Eron, JJ; Kenney, KB; Pereira, AS; Tidwell, RR | 1 |
| Ait-Khaled, M; Brosgart, CL; Eron, JJ; Falloon, J; Feinberg, J; Flanigan, TP; Hammer, SM; Kraus, PW; Masur, H; Murphy, R; Thomas, DA; Torres, R | 1 |
| Gao, W; Kishida, T; Okamoto, H; Shibata, N; Takada, K; Yoshikawa, Y | 1 |
| Elston, R; Harris, W; Klein, A; Maguire, M; Manohitharajah, V; May, J; Parker, H; Randall, S; Shortino, D; Snowden, W; Tisdale, M; Xu, F; Yeo, J | 1 |
| Sadler, BM; Sale, M; Stein, DS | 1 |
| Solignac, M | 1 |
| Andersson, J; Cooper, D; Goh, LE; Hoen, B; Janossy, G; Kinloch, S; Lampe, F; Perrin, L; Tilling, R; Tsoukas, C; Zaunders, J | 1 |
| Jaillon, P; Poirier, JM; Robidou, P | 2 |
| Jain, RG; Lenhard, JM | 1 |
| Corral, A; de Mendoza, C; Gallego, O; Soriano, V | 1 |
| Beauchaine, J; Clotet, B; D'Aquila, RT; Frost, SD; Martinez-Picado, J; Petropoulos, CJ; Prado, JG; Ruiz, L; Wrin, T | 1 |
| Bonaventure-Paci, S; Demarles, D; Fosse, S; Gillotin, C; Taburet, AM; Vincent, I | 1 |
| Brill, M; Farthing, C; Graham, E; Khanlou, H | 1 |
| Alexander, C; Harris, M; Montaner, JS; O'Shaughnessy, M | 1 |
| Piliero, PJ | 1 |
| Perrin, L | 1 |
| Edno-Mcheik, L; Lagrange, F; Molimard, M; Moore, N; Péhourcq, F; Titier, K | 1 |
| Brouwer, KR; Edwards, JE; McNamara, PJ | 1 |
| Aberg, JA; Bennett, KK; Bessen, LJ; Brosgart, C; DeGruttola, V; Eron, JJ; Gulick, RM; Hammer, SM; Holohan, MK; Karol, CN; Lewis, RH; Mellors, JW; Mitsuyasu, RT; Rogers, MD; Saah, AJ; Sheiner, L; Vaida, F; Valentine, FT; Wheat, LJ | 1 |
| Elston, RC; Furfine, E; Griffin, P; Guinea, R; Hanlon, MH; Kleim, JP; Macmanus, S; Maguire, MF; Parkin, N; Petropoulos, C; Porter, DJ; Richards, N; Snowden, BW; Tisdale, M; Wolfram, J; Wrin, T | 1 |
| Bihel, F; Bonnet, B; Chermann, JC; Courcambeck, J; De Michelis, C; Kraus, JL; Priem, G; Rocheblave, L | 1 |
| Acosta, EP; Eron, JJ; Fiscus, SA; Gerber, JG; Gulick, RM; Murphy, RL; Pereira, AS; Smeaton, LM; Snyder, S; Tidwell, RR | 1 |
| Freire, E; Ohtaka, H; Velázquez-Campoy, A; Xie, D | 1 |
| Buchanan, TA; Dubé, MP; Edmondson-Melançon, H; Goodwin, D; Johnson, D; Martinez, C; Qian, D; Sattler, FR; Williams, V | 1 |
| Bye, C; Falcoz, C; Fuder, H; Hardman, TC; Jenkins, JM; Kenney, KB; Prince, WT; Studenberg, S | 1 |
| Gamarnik, A; Parkin, N; Resch, W; Swanstrom, R; Ziermann, R | 1 |
| Gao, W; Kageyama, M; Kimura, K; Kishida, T; Shibata, N; Takada, K; Yoshikawa, Y | 1 |
| Bagossi, P; Boross, P; Copeland, TD; Fehér, A; Harrison, RW; Louis, JM; Mahalingam, B; Torshin, IY; Tözsér, J; Weber, IT | 1 |
| Bennett, KK; Hammer, SM; Labbé, L; Lu, JF; Mellors, J; Pfister, M; Rosenkranz, S; Sheiner, LB | 1 |
| Chaudry, NI; Eron, JJ; Fiscus, SA; Kashuba, AD; Naderer, OJ; Pereira, AS; Wire, MB | 1 |
| Bates, SM; Nakielny, RA; Page, KB; Talbot, MD | 1 |
| Bacconier, J; Basso, S; Durand, A; Lacarelle, B; Poizot-Martin, I; Quinson, AM; Ravaux, I; Solas, C | 1 |
| Aweeka, FT; Chi, J; Jayewardene, AL; Motoya, T; Stone, JA | 1 |
| Bates, M; Chappey, C; Hellmann, NS; Maroldo, L; Parkin, N; Petropoulos, CJ | 1 |
| Fusco, G; Liao, Q; Paulsen, D; Ross, L; Shaefer, M; St Clair, M | 1 |
| Fenton, M; Hall, M; Tong, C | 1 |
| Gaylord, G | 1 |
| Garrett, M; Hee, B; Kerr, BM; Petersen, C; Tran, JQ | 1 |
| Bidault, R; Bollens, D; Choudet, N; Demarles, D; Gillotin, C; Goujard, C; Meynard, JL; Rousseau, C; Taburet, AM; Vincent, I | 1 |
| Ershov, FI; Kas'ianova, NV; Vasil'ev, AN | 1 |
| Brosen, K; Justesen, US; Klitgaard, NA; Pedersen, C | 2 |
| Ait Mohand, H; Bonmarchand, M; Bossi, P; Bricaire, F; Cacace, R; Calvez, V; Costagliola, D; Delaugerre, C; Katlama, C; Ktorza, N; Lamotte, C; Marcelin, AG; Peytavin, G; Simon, A; Wirden, M | 1 |
| Fukumoto, K; Fukushima, K; Gao, W; Inoue, Y; Kageyama, M; Nishimura, A; Shibata, N; Tadano, J; Takada, K; Yamasaki, D; Yoshikawa, Y | 1 |
| Bowers, G; Cazali, N; Cresteil, T; Pons, G; Rey, E; Sonnier, M; Tréluyer, JM | 1 |
| Hamm, G; Hube, B; Korting, HC; Krnjaic, N; Niewerth, M; Schaller, M | 1 |
| Bogner, JR; Eberle, J; Goebel, FD; Troendle, U | 1 |
| Aarnoutse, RE; Burger, DM; Droste, JA; Hekster, YA; Koopmans, PP | 1 |
| Chappey, C; Parkin, NT; Petropoulos, CJ | 1 |
| Zolopa, AR | 1 |
| Ait-Khaled, M; Falloon, J; Griffin, P; Rakik, A; Richards, N; Stone, C; Thomas, D; Tisdale, M | 1 |
| DiFrancesco, R; Frerichs, VA; Keil, K; Morse, G | 1 |
| Gathe, JC; Griffith, S; Hernandez, JE; Lancaster, CT; Liao, Q; Nadler, JP; Pappa, KA; Pollard, RB; Richmond, GJ | 1 |
| Korn, K; Moschik, G; Paatz, C; Schmidt, B; Schnell, T; Thein, C; Walter, H | 1 |
| Brenner, B; Detorio, M; Diallo, K; Götte, M; Moisi, D; Oliveira, M; Wainberg, MA | 1 |
| Bates, M; Hellmann, N; Huang, W; Petropoulos, C; Wrin, T | 1 |
| Hruz, PW; Koster, JC; Nichols, CG; Qiu, H; Remedi, MS | 1 |
| Bevans, P; Furfine, E; Kazmierski, WM; Spaltenstein, A; Yang, H | 1 |
| Berenson, CS; Cloen, D; DiFrancesco, R; Giovanniello, AA; Hewitt, RG; Keil, K; Shelton, MJ | 1 |
| Bassetti, D; Bassetti, M; Ciravegna, BW; Di Biagio, A; Ferrazin, A; Rosso, R | 1 |
| Elston, R; Paulsen, D; Ross, L; Snowden, W; Tisdale, M | 1 |
| Cammalleri, C; Colby-Germinario, SP; Germinario, RJ; Wainberg, MA | 1 |
| Bilcer, G; Boross, P; Devasamudram, T; Gaddis, L; Ghosh, AK; Harrison, RW; Kincaid, JF; Koh, Y; Maeda, K; Mitsuya, H; Nakata, H; Ogata, H; Tie, Y; Volarath, P; Wang, YF; Weber, IT | 1 |
| Becker, S; Carlson, M; DeJesus, E; Delehanty, J; DeMasi, R; Haas, FF; Haubrich, R; Henry, D; Lalezari, JP; Northfelt, DW; Powderly, W; Richmond, G; Riddler, S; Salgo, M; Sista, PR; Thompson, M; Valentine, F; Wolfe, P; Wright, D | 1 |
| Cane, PA; de Ruiter, A; Easterbrook, PJ; Fisher, M; Leen, C; Li, X; Murphy, M; Pillay, D; Sabin, CA; Vlahakis, E; Wilkins, E | 1 |
| Ailhaud, G; Azoulay, S; Dani, C; Duval, D; Guedj, R; Vernochet, C | 1 |
| Lam, E; Parkin, NT | 1 |
| Carosi, G; Donati, E; Lo Caputo, S; Mazzotta, F; Moretti, F; Patroni, A; Quiros-Roldan, E; Scudeller, L; Torti, C; Vivarelli, A | 1 |
| Bilello, JA; Drusano, GL; Piliero, PJ; Preston, SL; Stein, DS; Symonds, WT | 1 |
| Auclair, M; Capeau, J; Caron, M; Kornprobst, M; Sterlingot, H | 1 |
| Aquaro, S; Caliò, R; Di Santo, F; Francesconi, M; Guenci, T; Perno, CF | 1 |
| Bassetti, D; Castagna, A; De Pascalis, CR; Fusetti, G; Galli, A; Gianotti, N; Guffanti, M; Lazzarin, A; Seminari, E | 1 |
| Arasteh, K; Eron, J; Millard, J; Naderer, OJ; Pollard, RB; Raffi, F; Stellbrink, HJ; Teofilo, E; Wire, MB; Wood, R; Yeo, J | 1 |
| Berger, F; Jaeger, H; Kurowski, M; Mauss, S; Rockstroh, JK; Schmutz, G; Scholten, S; Wolf, E | 1 |
| Joseph, AT; Khoo, SH | 1 |
| Bulgheroni, E; Chou, TC; Citterio, P; Croce, F; Galli, M; Lo Cicero, M; Rusconi, S; Soster, F; Viganò, O | 1 |
| Baker, CT; Furfine, ES; Hale, MR; Reynolds, DJ; Salisbury, JA; Searle, AD; Spaltenstein, A; Studenberg, SD; Todd, D; Tung, RD | 1 |
| de Mendoza, C; González de Requena, D; González-Lahoz, J; Martin-Carbonero, L; Soriano, V; Valer, L | 1 |
| Ballow, C; Hendrix, CW; Lou, Y; Piliero, PJ; Preston, SL; Stein, DS; Wire, MB | 1 |
| Barrail, A; Chêne, G; Clavel, F; Droz, C; Girard, PM; Le Tiec, C; Morand-Joubert, L; Raguin, G; Taburet, AM; Vincent, I | 1 |
| Chou, S; Marousek, GI; Murphy, MD | 1 |
| Boeri, E; Castagna, A; Danise, A; Gianotti, N; Hasson, H; Lazzarin, A; Nozza, S; Seminari, E | 1 |
| Baldini, F; Cauda, R; Cingolani, A; De Luca, A; Di Giambenedetto, S; Hoetelmans, RM | 1 |
| Brun-Vezinet, F; Clavel, F; Collin, G; Costagliola, D; Dalban, C; Descamps, D; Girard, PM; Lastere, S | 1 |
| DeGoey, DA; Randolph, JT | 1 |
| Belohradsky, BH; Engelhorn, C; Hoffmann, F; Kruse, G; Kurowski, M; Notheis, G; Stocker, H; Wintergerst, U | 1 |
| Barnaby, RJ; Baughman, TM; Bertolotti, L; Humphreys, JE; Jordan, KH; Mote, AL; Polli, JW; Read, KD; Serabjit-Singh, CJ; Vitulli, G; Webster, LO | 1 |
| Corbett, AH; Eron, JJ; Fiscus, SA; Kashuba, AD; Rezk, NL | 1 |
| Boulmé, R; Clevenbergh, P; Dellamonica, P; Kirstetter, M | 1 |
| Cattelan, AM; Clumeck, N; Katlama, C; Marquez, M; Pedro, Rde J; Pulido, F; Thomas, R; Tymkewycz, P; Zhu, C | 1 |
| Honda, Y; Izawa, K; Katayama, S; Kishibata, N; Kojima, M; Suzuki, T | 1 |
| Affolabi, D; Bossi, P; Bricaire, F; Calvez, V; Costagliola, D; Delaugerre, C; Katlama, C; Ktorza, N; Lamotte, C; Marcelin, AG; Mohand, HA; Peytavin, G; Voujon, D; Wirden, M | 1 |
| Angarano, G; Carosi, G; Lo Caputo, S; Mazzotta, F; Monno, L; Patroni, A; Quiros-Roldan, E; Saracino, A; Tinelli, C; Tirelli, V; Torti, C | 1 |
| Chappuy, H; Dimet, J; Firtion, G; Fouché, M; Mandelbrot, L; Pons, G; Rey, E; Tréluyer, JM | 1 |
| Arasteh, K; Eron, J; Livrozet, JM; Millard, J; Naderer, OJ; Teofilo, E; Trepo, C; Wire, MB; Wood, R; Yeo, J | 1 |
| Brill, M; Campo, R; Chu, HM; Garg, V; Jayaweera, DT; Kolber, MA; Rodriguez, A; Tanner, T | 1 |
| Buchanan, TA; Considine, RV; Deeg, MA; Degawa-Yamauchi, M; Dubé, MP; Edmondson-Melançon, H; Hernandez, J; Sattler, FR; Shankar, S; Young, EM | 1 |
| Chêne, G; Clavel, F; Droz, C; Girard, PM; Le Tiec, C; Morand-Joubert, L; Raguin, G; Taburet, AM | 1 |
| Bigelow, GE; Christopher, J; Fuchs, EJ; Hendrix, CW; Lou, Y; Martinez, E; Snidow, JW; Wakeford, J; Wire, MB | 1 |
| de Béthune, MP; King, NM; Nalivaika, EA; Prabu-Jeyabalan, M; Schiffer, CA; Wigerinck, P | 1 |
| Blanche, S; Johnson, M; Lou, Y; Randall, S; Stein, DS | 1 |
| Aldinger, T; Ayrton, A; Bentz, J; Ellens, H; Mittal, A; Polli, JW; Tran, TT | 1 |
| Carter, HL; Danger, D; Furfine, ES; Hanlon, MH; Kaldor, IW; Miller, JF; Porter, DJ; Samano, VA; Shu, AY; Spaltenstein, A | 1 |
| Klein, HH; Meier, M; Schütt, M; Zhou, J | 1 |
| Chadwick, EG; Homans, JD; Kovacs, A; Lou, Y; Symonds, WT; Yogev, R | 1 |
| Baker, KL; Ford, SL; Lou, Y; Stein, DS; Wire, MB | 1 |
| Acosta, EP; Collier, AC; Downey, GF; Eshleman, SH; Kashuba, AD; Klingman, K; Mellors, JW; Scott, TR; Tierney, C; Vergis, EN | 1 |
| Arvieux, C; Tribut, O | 1 |
| Jenwitheesuk, E; Samudrala, R | 1 |
| Boutton, CW; De Bondt, HL; De Jonge, MR | 1 |
| Chen, YS; Hsu, MF; Tsai, JJ; Wang, JP | 1 |
| Dekhtyar, T; Flentge, CA; Kempf, DJ; Klein, LL; Randolph, JT; Stoll, VS; Sun, M; Yeung, CM; Zhao, C | 1 |
| Brown, AJ; Clotet, B; Frost, SD; Martinez-Picado, J; Parkin, NT; Petropoulos, CJ; Ruiz, L; Wrin, T | 1 |
| Arnedo, M; Biglia, MA; Blanco, JL; García, F; Gatell, JM; Laguno, M; Larrousse, M; Leon, A; Lonca, M; Mallolas, J; Martínez, E; Milinkovic, A; Miró, JM; Pumarola, T | 1 |
| Ieki, R; Iguchi, M; Kato, T; Okamura, T; Ota, T; Saito, E; Shibuya, M; Yuasa, K | 1 |
| Castagna, A; Cusato, M; Fusetti, G; Galli, A; Gianotti, N; Guffanti, M; Lazzarin, A; Regazzi, M; Seminari, E; Villani, P | 1 |
| Adams, E; Brizz, B; Difrancesco, R; Morse, GD; Para, MF; Reichman, RC; Rosenkranz, S; Segal, Y; Yarasheski, KE | 1 |
| Chai, H; Chen, C; Li, M; Lin, PH; Lumsden, AB; Yan, S; Yang, H; Yao, Q | 1 |
| Ayrton, A; Bentz, J; Ellens, H; Polli, JW; Tran, TT | 1 |
| Hruz, PW; Yan, Q | 1 |
| El-Shourbagy, TA; Fan, L; Kim, GE; Naxing Xu, R | 1 |
| Allred, KF; Smart, EJ; Wilson, ME | 1 |
| Elston, R; Kleinkauf, N; Schürmann, D; Suttorp, N; Wünsche, T; Xu, F | 1 |
| Bhatti, L; Farthing, C; Khanlou, H | 1 |
| Augustijns, P; Brouwers, J; Lammert, F; Tack, J | 1 |
| Barrail, A; Furlan, V; Le Tiec, C; Paci-Bonaventure, S; Taburet, AM; Vincent, I | 1 |
| Backman, JT; Granfors, MT; Kajosaari, LI; Laitila, J; Neuvonen, PJ; Wang, JS | 1 |
| Shelton, MJ; Studenberg, S; Wire, MB | 1 |
| Chang, CE; McCammon, JA; Shen, T; Tozzini, V; Trylska, J | 1 |
| Baker, KL; Berrey, MM; Jones, LS; Lou, Y; Shelton, MJ; Thomas, GJ; Wire, MB | 1 |
| Bagossi, P; Boross, P; Fehér, A; Kádas, J; Miklóssy, G; Oroszlan, S; Sperka, T; Tözsér, J; Weber, IT | 1 |
| Bacheler, L; Corral, A; de Mendoza, C; Pattery, T; Soriano, V; Valer, L | 1 |
| Borland, J; Ford, SL; Lou, Y; Min, SS; Shelton, MJ; Wire, MB; Xue, ZG; Yuen, G | 1 |
| Huynh, P; Kohli-Pamnani, A; Lobo, F | 1 |
| Bonora, S; Cocchi, S; Codeluppi, M; Di Benedetto, F; Esposito, R; Gennari, W; Gerunda, GE; Guaraldi, G; Luzi, K; Masetti, M; Motta, A; Pecorari, M | 1 |
| Li, WP; Schutt, M; Xiang, Z; Zhou, JQ | 1 |
| Chang, MS; El-Shourbagy, TA; Kim, EJ | 1 |
| Harrer, T; Horn, AH; Meiselbach, H; Sticht, H | 1 |
| Furfine, E; Kazmierski, WM; Spaltenstein, A; Wright, LL | 1 |
| de Hoon, J; Van Wijngaerden, E; Verbesselt, R | 1 |
| Balfour, HH; Brundage, RC; Vezina, HE; Weller, DR | 1 |
| Lancaster, CT; Lou, Y; Luber, AD; Pappa, KA; Ruane, PJ; Shelton, MJ; Wire, MB | 1 |
| Doron-Faigenboim, A; Pupko, T | 1 |
| Brenner, BG; Moisi, D; Ntemgwa, M; Oliveira, M; Wainberg, MA | 1 |
| Acharya, P; Ayrton, A; Bentz, J; Ellens, H; Polli, JW; Tran, TT | 1 |
| Chêne, G; Clavel, F; Girard, PM; Le Tiec, C; Morand-Joubert, L; Poizat, G; Raguin, G; Taburet, AM | 1 |
| Augustijns, P; Brouwers, J; Tack, J | 2 |
| Choi, SO; Kashuba, AD; Rezk, NL | 1 |
| Chang, CE; Chen, W; Gilson, MK | 1 |
| Adams, E; Bilic, S; DiFrancesco, R; Forrest, A; Morse, GD; Okusanya, O; Para, MF; Reichman, RC; Rosenkranz, S; Yarasheski, KE | 1 |
| Hou, T; Yu, R | 1 |
| Berthé, H; de Truchis, P; Delaugerre, C; Galperine, T; Long, K; Mathez, D; Peytavin, G | 1 |
| Ballow, CH; Borland, J; Lewis, EW; Lin, J; Lou, Y; Shelton, MJ; Wire, MB; Yuen, G | 1 |
| Banik, N; Breske, A; Kruse, G; Kurowski, M; Mazur, D; Richter, H; Stocker, H; Walli, RK | 1 |
| Crane, HM; Harrington, RD; Kestenbaum, B; Kitahata, MM | 1 |
| Bastiani, E; Benedetti, F; Berti, F; Campaner, P; Donadel, E; Montagna, M; Regazzi, M; Rinaldi, S; Savoini, A; Venturini, R | 1 |
| Castagna, A; De Bona, A; Dorigatti, F; Galli, L; Gentilini, G; Gianotti, N; Lazzarin, A; Schira, G; Seminari, E; Soldarini, A; Uberti-Foppa, C | 1 |
| De Bona, A; Dorigatti, F; Galli, L; Gentilini, G; Seminari, E; Soldarini, A; Spagnuolo, V; Uberti-Foppa, C | 1 |
| Adams, E; Hoogmartens, J; Van Schepdael, A; Yekkala, R | 1 |
| Asmuth, DM; Kung, HJ; Libertini, SJ; Mudryj, M; Rodriguez, V; Tepper, CG | 1 |
| Barditch-Crovo, P; Carson, KA; Flexner, C; Hendrix, CW; Khan, W; Pakes, GE; Parish, M; Parsons, T; Pham, PA; Qaqish, R; Radebaugh, C | 1 |
| Acharya, P; Ayrton, A; Bentz, J; Ellens, H; O'Connor, MP; Polli, JW | 1 |
| Deray, G; Izzedine, H; Janus, N; Karie, S; Launay-Vacher, V; Laville, I | 1 |
| Bui, T; Ho, RJ; Hsiao, P; Unadkat, JD | 1 |
| Aweeka, F; Grunfeld, C; Lee, GA; Lo, JC; Mulligan, K; Rao, M; Schambelan, M; Schwarz, JM | 1 |
| de Béthune, MP; De Meyer, S; Picchio, G | 1 |
| Bruzzone, B; Cenderello, G; Dentone, C; Di Biagio, A; Ferrea, G; Icardi, G; Mularoni, A; Rosso, R; Viscoli, C | 1 |
| Allavena, C; Biron, C; Dailly, E; Jolliet, P; Raffi, F | 1 |
| Alonzi, T; Ascenzi, P; Mancone, C; Narciso, P; Notari, S; Tripodi, M | 1 |
| Barrail-Tran, A; Chêne, G; Clavel, F; Dam, E; Girard, PM; Le Tiec, C; Morand-Joubert, L; Poizat, G; Raguin, G; Taburet, AM | 1 |
| Diaz, RS; Ferreira, PA; Tenore, S | 1 |
| Delgado, O; Murillas, J; Riera, M; Ventayol, P | 1 |
| Ali, A; Altman, MD; Anjum, SG; Cao, H; Chellappan, S; Fernandes, MX; Gilson, MK; Kairys, V; Nalam, MN; Rana, TM; Reddy, GS; Schiffer, CA; Tidor, B | 1 |
| Bigelow, GE; Cao, YJ; Causon, RC; Fuchs, EJ; Hendrix, CW; Lancaster, CT; Lou, Y; Martinez, E; McCabe, S; Radebaugh, C; Smith, PF; Wire, MB | 1 |
| Feicke, A; Oertle, D; Rentsch, KM; Strebel, RT | 1 |
| Cheung, C; Gonzalez, FJ; Idle, JR; Krausz, KW; Ma, X; Shah, YM; Wang, T | 1 |
| Ghosh, AK; Kovalevsky, AY; Weber, IT | 1 |
| Louis, JM; Sayer, JM | 1 |
| Boesmans, D; Di Fazio, V; Elens, L; Haufroid, V; Vanbinst, R; Veriter, S; Wallemacq, P | 1 |
| Allison, TJ; Coburn, CA; Dandache, S; Holloway, MK; Oliveira, M; Panchal, C; Stranix, BR; Vacca, JP; Wainberg, MA; Wu, JJ | 1 |
| Aoki, M; Aoki-Ogata, H; Koh, Y; Maeda, K; Mitsuya, H; Miyakawa, T; Venzon, DJ; Yoshimura, K | 1 |
| Hidalgo Tenorio, C; Pasquau Liaño, J | 1 |
| Anderson, PL; Clay, PG; Glaros, AG; McRae, M | 1 |
| Dyachenko, A; Grunfeld, C; Kim, S; Lee, GA; Mulligan, K; Patzek, S; Schambelan, M; Schwarz, JM; Wen, M | 1 |
| Bihani, SC; Das, A; Ferrer, JL; Hosur, MV; Prashar, V | 1 |
| Chen, J; Chen, L; Gurley, E; Hylemon, PB; Pandak, WM; Sanyal, AJ; Studer, E; Sun, L; Wang, G; Wang, JY; Wang, X; Wu, X; Zha, W; Zhang, L; Zhou, H | 1 |
| Andrews, M; Condoluci, DV; Luber, AD; Olson, K; Pakes, GE; Pappa, KA; Peloquin, CA; Slowinski, PD | 1 |
| Braga-Silva, LA; Mogami, SS; Santos, AL; Silva-Neto, ID; Valle, RS | 1 |
| Dirauf, P; Meiselbach, H; Sticht, H | 1 |
| Ciurlionis, R; Degoey, DA; Kempf, DJ; Klein, LL; Marsh, K; Randolph, JT; Spear, B; Waring, JF | 1 |
| Annaert, P; Augustijns, P; Camus, S; Ye, ZW | 1 |
| Alam, S; Dinello, D; Israr, M; Kishel, JJ; Meyers, C; Mitchell, D | 1 |
| Blanco, J; Bofill, M; Cabrera, C; Clotet, B; Cunyat, F; Marfil, S; Puig, T; Ruiz, L | 1 |
| Annaert, P; Augustijns, P; Brouwers, J; Mols, R | 1 |
| Boccara, F; Costagliola, D; Cotte, L; Gilquin, J; Lang, S; Mary-Krause, M; Partisani, M; Simon, A | 1 |
| Harrison, RW; Kovalevsky, AY; Shen, CH; Wang, YF; Weber, IT | 1 |
| Baki, L; Baumgarten, CM; Deng, W; Yin, J; Zhou, H | 1 |
| Kempf, DJ; Norton, M; Parkin, NT; Pilot-Matias, T; Stawiski, E; Trinh, R; Young, TP | 1 |
| Agniswamy, J; Amano, M; Aoki, M; Baldridge, A; Ghosh, AK; Miguel, SG; Mitsuya, H; Rao, KV; Wang, YF; Weber, IT; Xu, CX | 1 |
| Adnot, S; Amsellem, V; Brégeon, J; Dubois-Randé, JL; Gary-Bobo, G; Houssaini, A; Marcos, E; Pacaud, P; Perrin, A; Rideau, D; Savale, L; Sitbon, O | 1 |
| Browning, MR; Drexler, DM; Morgan, DG; Olah, TV | 1 |
| de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Picchio, G; Spinosa-Guzman, S; Van De Casteele, T; Vanden Abeele, C | 1 |
| Amano, M; Aoki, M; Chapsal, B; Das, D; Ghosh, AK; Ide, K; Koh, Y; Leschenko, S; Mitsuya, H; Yedidi, RS | 1 |
| Hoffmann, HH; Kunz, A; Palese, P; Shaw, ML; Simon, VA | 1 |
| Nsanzabana, C; Rosenthal, PJ | 1 |
| Cieplak, P; Deng, NJ; Lai, L; Zhang, P | 1 |
| Dunn, BM; Goldfarb, NE; Gustchina, A; Li, M; Matúz, K; Namwong, S; Tözsér, J; Wlodawer, A | 1 |
| Abraham, F; Acharya, P; Agnani, D; Bentz, J; Ellens, H; Martinez, E; Tobin, F; Tran, TT | 1 |
| Borkowsky, W; DiMeglio, LA; Geffner, ME; Hazra, R; Jacobson, DL; Miller, TL; Patel, K; Silio, M; Van Dyke, RB; Worrell, C | 1 |
| Appel, DI; Markowitz, JS; Peloquin, CA; Peterson, YK; Rhoades, JA; Zhu, HJ | 1 |
| Boross, PI; Chiu, TY; Ghosh, AK; Harrison, RW; Louis, JM; Tie, Y; Tozser, J; Wang, YF; Weber, IT | 1 |
| Best, BM; Capparelli, E; Clifford, DB; Collier, AC; Croteau, D; Ellis, RJ; Gelman, BB; Grant, I; Letendre, S; Marra, CM; McArthur, J; McCutchan, JA; Morgello, S; Rossi, SS; Simpson, DM; Way, L | 1 |
| Hu, Y; Huang, N; Li, S; Xing, W; Yan, J; Yang, LM; Zheng, YT | 1 |
| Abecasis, AB; Arts, EJ; Camacho, RJ; Diaz, RS; Herchenröder, O; Lalonde, MS; Ratcliff, A; Santos, AF; Soares, MA; Tebit, DM | 1 |
| Kar, P; Knecht, V | 1 |
| Aalinkeel, R; Law, WC; Mahajan, SD; Nair, BB; Prasad, PN; Reynolds, J; Roy, I; Schwartz, SA; Yong, KT | 1 |
| Baldi, A; Chirianni, A; De Luca, A; Esposito, V; Gargiulo, M; Lucariello, A; Manente, L; Parrella, G; Parrella, R; Perna, A; Viglietti, R | 1 |
| Furukawa, A; Katahira, M; Matsunaga, S; Morishita, R; Ode, H; Ryo, A; Sakuma, R; Sato, H; Sawasaki, T; Sugiura, W; Takaori-Kondo, A; Yamamoto, N | 1 |
| Furukawa, A; Ikegami, T; Katahira, M; Kobayashi, N; Kodaki, T; Matsunaga, S; Morishita, R; Nagata, T; Okamura, H; Ryo, A; Takaori-Kondo, A | 1 |
| Baldi, A; Chirianni, A; De Luca, A; Esposito, V; Galati, R; Manente, L; Montesarchio, V; Pagliano, P; Parrella, G; Parrella, R; Spugnini, EP; Verdina, A; Viglietti, R | 1 |
| Liu, L; Unadkat, JD | 1 |
| Cau, P; Cremer, J; Dellamonica, P; Faucher, O; Kaspi, E; Lacarelle, B; Lévy, N; Micallef, J; Nicolino-Brunet, C; Perrin, S; Poizot-Martin, I; Reynes, J; Robaglia-Schlupp, A; Roll, P; Solas, C; Stretti, C; Tamalet, C; Tamalet, CN | 1 |
| Bandaranayake, RM; King, NM; Mittal, S; Nalam, MN; Nalivaika, EA; Prabu-Jeyabalan, M; Schiffer, CA; Yilmaz, NK | 1 |
| Amano, M; Aoki, M; Campbell, JR; Das, D; Ghosh, AK; Mitsuya, H; Rao, KV; Salcedo-Gómez, PM; Tojo, Y; Xu, CX | 1 |
| Ai, N; Helsley, RN; Park, SH; Sui, Y; Welsh, WJ; Zhou, C | 1 |
| Agniswamy, J; Ghosh, AK; Louis, JM; Rao, KV; Sayer, JM; Shen, CH; Wang, YF; Weber, IT; Xu, CX | 1 |
| Commenges, D; Drylewicz, J; Guedj, J; Prague, M; Thiébaut, R | 1 |
| Blakeley, MP; Ghosh, AK; Keen, DA; Kovalevsky, AY; Langan, P; Mustyakimov, M; Waltman, MJ; Weber, IT | 1 |
| Bridges, AS; Dufek, MB; Thakker, DR | 1 |
| Leonis, G; Papadopoulos, MG; Steinbrecher, T | 1 |
| Bow, DA; Chiou, WJ; de Morais, SM; Kikuchi, R; Li, X; Voorman, RL | 1 |
| Ahmed, Z; Bentz, J; Ellens, H; Hidalgo, IJ; Li, J; Li, L; Lumen, AA; Meng, Z; Owen, A | 1 |
| Borland, J; Chen, S; Peppercorn, A; Piscitelli, SC; Song, I; Wajima, T | 1 |
| Haugaard, SB | 1 |
| Barbour, AM; Gibiansky, L; Wire, MB | 1 |
| Chen, J; Liang, Z; Wang, W; Yi, C; Zhang, Q; Zhang, S | 1 |
| Branquinha, MH; D Avila-Levy, CM; Menna-Barreto, RF; Sangenito, LS; Santos, AL | 1 |
| Amano, M; Das, D; Ghosh, AK; Mitsuya, H; Nyalapatla, PR; Parham, GL; Salcedo-Gómez, PM; Tojo, Y | 1 |
| Shao, Q; Shi, J; Wang, J; Yu, Y; Zhu, W | 1 |
| Duan, R; Lazim, R; Zhang, D | 1 |
| Aweeka, F; Collier, AC; Dumond, JB; Kashuba, AD; Mollan, K; Rigdon, J; Tierney, C | 1 |
| Raines, RT; Windsor, IW | 1 |
| Chen, J; Wang, X; Zhang, JZ; Zhang, Q; Zhu, T | 1 |
| Acharjee, S; Asahchop, EL; Baker, GB; Power, C; Vivithanaporn, P | 1 |
| Ganapathi, U; Gunaseelan, S; Myers, DR; Nelson, AG; Palombo, MS; Samizadeh, M; Singh, Y; Sinko, PJ; Szekely, Z; Zhang, X | 1 |
| Alibés, A; Gil, V; Guallar, V; Hosseini, A; Noguera-Julian, M; Orozco, M; Paredes, R; Soliva, R | 1 |
| Amano, M; Bulut, H; Das, D; Delino, NS; Ghosh, AK; Mitsuya, H; Salcedo-Gómez, PM; Sheri, VR; Yedidi, RS; Zhao, R | 1 |
| Bentz, J; Ellens, H; Meng, Z | 1 |
| Bao, J; Chen, J; Huang, G; Jiang, W; Li, C; Li, T; Li, X; Qi, P; Shi, W; Wang, H; Wang, Y | 1 |
| Alteri, C; Aquaro, S; Borrajo, A; Bruno, R; Modesti, A; Perno, CF; Pollicita, M; Ranazzi, A; Svicher, V | 1 |
| Camproux, AC; Cano Contreras, ME; Descamps, D; Flatters, D; Regad, L; Triki, D; Visseaux, B | 1 |
| Chen, J; Peng, C; Wang, J; Zhu, W | 1 |
| Augustijns, P; Braeckmans, M; Brouwers, J; Masuy, I; Servais, C; Tack, J | 1 |
| Alviano, DS; Gonçalves, DS; Granato, MQ; Kneipp, LF; Pessolani, MCV; Rosa, TLSA; Santos, ALS; Seabra, SH; Sousa, IS | 1 |
| Wang, RG; Zhang, HX; Zheng, QC | 1 |
| Deeks, HM; Glowacki, DR; Hare, SR; Mulholland, AJ; O'Connor, MB; Walters, RK | 1 |
| Behera, S; Das, P; Ghosh, P; Kumari, B; Mandal, A; Mazire, PH; Purkait, B; Roy, A | 1 |
| Liu, WT; Sun, HB; Wang, W; Wu, SL; Yu, YX; Zhang, LL | 1 |
27 review(s) available for carbamates and amprenavir
| Article | Year |
|---|---|
In vitro selection and characterization of VX-478 resistant HIV-1 variants.
Topics: Carbamates; Drug Resistance; Furans; Genetic Variation; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Protein Conformation; Sulfonamides | 1998 |
Amprenavir.
Topics: Animals; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; In Vitro Techniques; Rats; RNA, Viral; Sulfonamides | 1998 |
Resistance to human immunodeficiency virus type 1 protease inhibitors.
Topics: Carbamates; Drug Resistance; Furans; HIV Protease; HIV Protease Inhibitors; Indinavir; Nelfinavir; Pyridines; Pyrones; Ritonavir; Saquinavir; Structure-Activity Relationship; Sulfonamides | 1998 |
Clinical update: new drugs for HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Chemistry, Pharmaceutical; Cyclopropanes; Dideoxynucleosides; Drug Approval; Furans; HIV Protease Inhibitors; Humans; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides | 1999 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
Coming therapies: amprenavir.
Topics: Anti-HIV Agents; Carbamates; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Sulfonamides | 1999 |
HIV protease as a target for retrovirus vector-mediated gene therapy.
Topics: Amino Acid Sequence; Carbamates; Furans; Genetic Therapy; Genetic Vectors; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lentivirus; Models, Molecular; Molecular Structure; Nelfinavir; Retroviridae; Ritonavir; Saquinavir; Sulfonamides; Transfection | 2000 |
Targeting the HIV-protease in AIDS therapy: a current clinical perspective.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Binding Sites; Carbamates; Clinical Trials as Topic; Computer-Aided Design; Crystallography, X-Ray; Drug Design; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Oligopeptides; Pyridines; Pyrones; Randomized Controlled Trials as Topic; Ritonavir; Saquinavir; Sulfonamides | 2000 |
Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor.
Topics: Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Furans; HIV Protease Inhibitors; Humans; Sulfonamides | 2000 |
Ongoing trials in HIV protease inhibitors.
Topics: Carbamates; Clinical Trials as Topic; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; United States; United States Food and Drug Administration | 2000 |
Amprenavir: a review of its clinical potential in patients with HIV infection.
Topics: Animals; Carbamates; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Molecular Structure; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome | 2000 |
[Pharmacological study and clinical effect of HIV protease inhibitor amprenavir].
Topics: Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Food-Drug Interactions; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Mixed Function Oxygenases; Sulfonamides | 2001 |
[Resistance to protease inhibitors].
Topics: Carbamates; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Mutation; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2001 |
Possible linkage of amprenavir with intracranial bleeding in an HIV-infected hemophiliac.
Topics: Adult; Carbamates; Diagnosis, Differential; Factor VIII; Furans; Hemophilia A; HIV Infections; HIV Protease Inhibitors; Humans; Intracranial Hemorrhages; Male; Sulfonamides; Tomography, X-Ray Computed | 2001 |
Penetration of HIV-1 protease inhibitors into CSF and semen.
Topics: Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nelfinavir; Ritonavir; Saquinavir; Semen; Sulfonamides; Viral Load | 2000 |
From amprenavir to GW433908.
Topics: Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Drug Resistance, Viral; Furans; HIV Infections; Humans; Organophosphates; Prodrugs; Sulfonamides | 2001 |
Clinical pharmacology and pharmacokinetics of amprenavir.
Topics: Carbamates; Drug Interactions; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Sulfonamides; Tissue Distribution | 2002 |
[A novel anti-HIV agent--agenerase].
Topics: Carbamates; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Sulfonamides | 2002 |
Practical applications of viral fitness in clinical practice.
Topics: Carbamates; Drug Resistance, Viral; Furans; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Models, Biological; Mutation; Sulfonamides; Viral Load; Virus Replication | 2003 |
Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects.
Topics: Carbamates; Drug Resistance, Viral; Furans; Genetic Linkage; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation; Phenotype; Pyrimidinones; Sulfonamides | 2003 |
Peptidomimetic inhibitors of HIV protease.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Dipeptides; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Models, Molecular; Molecular Mimicry; Molecular Structure; Nelfinavir; Oligopeptides; Organophosphates; Peptides; Phenylbutyrates; Pyridines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Urethane | 2004 |
Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Topics: Anti-HIV Agents; Carbamates; Drug Resistance; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Ritonavir; Sulfonamides | 2005 |
Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.
Topics: Adult; Carbamates; Drug Interactions; Furans; Half-Life; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Intestinal Absorption; Organophosphates; Prodrugs; Reverse Transcriptase Inhibitors; Sulfonamides; Tissue Distribution | 2006 |
Quality control of protease inhibitors.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Chromatography, Liquid; Darunavir; Drug Contamination; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Organophosphates; Pyridines; Pyrimidinones; Pyrones; Quality Control; Ritonavir; Saquinavir; Sulfonamides | 2008 |
Response to "key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients".
Topics: Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; Treatment Outcome | 2008 |
[Chemical characteristics, mechanism of action and antiviral activity of darunavir].
Topics: Administration, Oral; Carbamates; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Darunavir; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Molecular Structure; Ritonavir; Sulfonamides | 2008 |
Alteration in pancreatic islet function in human immunodeficiency virus.
Topics: Carbamates; Furans; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Indinavir; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Nelfinavir; Ritonavir; Sulfonamides | 2014 |
88 trial(s) available for carbamates and amprenavir
| Article | Year |
|---|---|
In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents.
Topics: Carbamates; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Pyridines; Quinolines; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides; Thiazoles; Valine | 1996 |
Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Furans; HIV Infections; Humans; Lamivudine; Male; Middle Aged; RNA, Viral; Sulfonamides; Zidovudine | 1999 |
Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults.
Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Biological Availability; Carbamates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Male; Middle Aged; Sulfonamides | 1999 |
Sampling lymphoid tissue cells by ultrasound-guided fine needle aspiration of lymph nodes in HIV-infected patients. Swiss HIV Cohort Study.
Topics: Anti-HIV Agents; Biopsy, Needle; Carbamates; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dideoxynucleosides; Drug Therapy, Combination; Flow Cytometry; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Longitudinal Studies; Lymph Nodes; Lymphocyte Activation; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonamides; Ultrasonography | 1999 |
A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nausea; RNA, Viral; Safety; Sulfonamides; Time Factors; Viremia; Zidovudine | 1999 |
Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men.
Topics: Adult; Antifungal Agents; Breath Tests; Carbamates; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Erythromycin; Furans; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Mixed Function Oxygenases; Sulfonamides; Time Factors | 1999 |
Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity.
Topics: Adult; Alkynes; Antiviral Agents; Area Under Curve; Base Sequence; Benzoxazines; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Furans; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Molecular Sequence Data; Mutation; Oxazines; Phenotype; Pilot Projects; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2000 |
Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function.
Topics: Adult; Area Under Curve; Carbamates; Female; Furans; HIV Protease Inhibitors; HIV-1; Humans; Liver Cirrhosis; Liver Diseases; Male; Middle Aged; Protein Binding; Sulfonamides | 2000 |
Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-HIV Agents; Area Under Curve; Biotransformation; Breath Tests; Carbamates; Clarithromycin; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Erythromycin; Furans; Half-Life; Humans; Liver Function Tests; Male; Mixed Function Oxygenases; Sulfonamides | 2000 |
The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850).
Topics: Adult; Carbamates; Double-Blind Method; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Regression Analysis; RNA, Viral; Semen; Sulfonamides; Virus Shedding; Zidovudine | 2000 |
Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.
Topics: Carbamates; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Phenotype; Protein Binding; Ritonavir; Saquinavir; Sulfonamides | 2000 |
Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy.
Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; Carbamates; CD4 Lymphocyte Count; CD4-CD8 Ratio; Dideoxynucleosides; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lymph Nodes; Lymphocyte Activation; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonamides; Viral Load | 2000 |
Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team.
Topics: Adolescent; Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonamides; Zidovudine | 2000 |
Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count.
Topics: Adult; Anti-HIV Agents; Antigens, Fungal; Antigens, Viral; Antiretroviral Therapy, Highly Active; Candida albicans; Carbamates; CD4 Lymphocyte Count; Chronic Disease; Cytomegalovirus; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Simplexvirus; Sulfonamides; T-Lymphocyte Subsets | 2000 |
Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing.
Topics: Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Carbamates; Dideoxynucleosides; Female; Furans; HIV Protease Inhibitors; HIV Seropositivity; Humans; Male; RNA, Viral; Sulfonamides | 2001 |
Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antibiotics, Antitubercular; Biotransformation; Breath Tests; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dealkylation; Drug Interactions; Erythromycin; Furans; Humans; Male; Middle Aged; Mixed Function Oxygenases; Rifabutin; Rifampin; Sulfonamides | 2001 |
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Male; Nevirapine; Odds Ratio; Prospective Studies; RNA, Viral; Safety; Stavudine; Sulfonamides; Time Factors; Treatment Outcome; Viral Load | 2001 |
In vivo effect of alpha(1)-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor.
Topics: Adolescent; Adult; Carbamates; Cross-Over Studies; Drug Interactions; Female; Furans; HIV Protease Inhibitors; Humans; Linear Models; Male; Metabolic Clearance Rate; Middle Aged; Orosomucoid; Sulfonamides | 2001 |
Safety profile and tolerability of amprenavir in the treatment of adult and pediatric patients with HIV infection.
Topics: Adolescent; Adult; Anti-HIV Agents; Carbamates; Child; Child, Preschool; Digestive System; Drug Therapy, Combination; Exanthema; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Paresthesia; Sulfonamides | 2000 |
Safety profile and tolerability of amprenavir in patients enrolled in an early access program.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Carbamates; Child; Child, Preschool; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Sulfonamides | 2001 |
Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects.
Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Black People; Breath Tests; Carbamates; Carbon Radioisotopes; Follow-Up Studies; Furans; Half-Life; HIV Seronegativity; HIV-1; Humans; Male; Middle Aged; Protease Inhibitors; Sulfonamides; White People | 2001 |
Open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and chronically HIV-1--infected patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS Dementia Complex; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Chronic Disease; Dideoxynucleosides; Digestive System; Drug Synergism; Ethnicity; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocyte Subsets; Male; Pregnancy; Research Design; RNA, Viral; Sulfonamides; Treatment Refusal; Zidovudine | 2001 |
Protease inhibitor trial started.
Topics: Acquired Immunodeficiency Syndrome; Adult; Carbamates; Furans; HIV Protease Inhibitors; Humans; Indinavir; Reverse Transcriptase Inhibitors; Sulfonamides | 1998 |
Preliminary data on 141W94 reported.
Topics: Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Sulfonamides; Zidovudine | 1998 |
Phase III results presented on amprenavir triple combination.
Topics: Anti-HIV Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Sulfonamides; Zidovudine | 1998 |
A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir.
Topics: Adult; Aged; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonamides; Treatment Outcome | 2001 |
Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers.
Topics: Administration, Oral; Adult; Body Mass Index; Carbamates; Diarrhea; Dose-Response Relationship, Drug; Drug Therapy, Combination; Exanthema; Female; Furans; HIV Protease Inhibitors; HIV Seronegativity; Humans; Male; Middle Aged; Nausea; Ritonavir; Statistics, Nonparametric; Sulfonamides | 2001 |
A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Carbamates; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maximum Tolerated Dose; Phenotype; Sulfonamides; Time Factors; Treatment Outcome | 2001 |
Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.
Topics: Adult; Area Under Curve; Carbamates; CD4 Lymphocyte Count; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Enzyme Inhibitors; Female; Furans; HIV Protease Inhibitors; HIV Seropositivity; Humans; Indinavir; Male; Mixed Function Oxygenases; Nelfinavir; Orosomucoid; Saquinavir; Sulfonamides | 2001 |
HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Female; Furans; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Phenotype; Retrospective Studies; RNA, Viral; Safety; Sulfonamides; Treatment Failure | 2002 |
Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleos
Topics: Carbamates; Cloning, Molecular; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; Genotype; HIV Core Protein p24; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Mutagenesis, Site-Directed; Nucleosides; Phenotype; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Sulfonamides | 2002 |
Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.
Topics: Adolescent; Adult; Algorithms; Anti-HIV Agents; Carbamates; Computer Simulation; Drug Interactions; Female; Furans; Humans; Male; Middle Aged; Models, Biological; Monte Carlo Method; Reproducibility of Results; Ritonavir; Sulfonamides | 2002 |
Single-dose pharmacokinetics of amprenavir coadministered with grapefruit juice.
Topics: Administration, Oral; Adult; Beverages; Carbamates; Citrus; Cross-Over Studies; Female; Food-Drug Interactions; Furans; HIV Protease Inhibitors; Humans; Male; Sulfonamides | 2002 |
Therapeutic vaccination in primary HIV infection, the Quest trial.
Topics: AIDS Vaccines; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Defective Viruses; Dideoxynucleosides; Furans; HIV Infections; Humans; Immunotherapy, Active; Lamivudine; Lymphocyte Count; Sulfonamides; T-Lymphocyte Subsets; Vaccination; Vaccinia virus; Viral Load; Viral Vaccines; Viremia; Zidovudine | 2002 |
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Disease Progression; Double-Blind Method; Drug Resistance, Viral; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Organophosphonates; Oxazines; Proportional Hazards Models; Reverse Transcriptase Inhibitors; Saquinavir; Sulfonamides; Treatment Failure; Viral Load | 2002 |
The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850).
Topics: Adult; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Furans; Genitalia, Male; HIV Infections; HIV-1; Humans; Lamivudine; Male; RNA, Viral; Semen; Statistics, Nonparametric; Sulfonamides; Zidovudine | 2002 |
Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers.
Topics: Adolescent; Adult; Area Under Curve; Capsules; Carbamates; Cross-Over Studies; Dose-Response Relationship, Drug; Fasting; Food-Drug Interactions; Furans; Health; Humans; Male; Middle Aged; Organophosphates; Prodrugs; Sulfonamides; Suspensions; Tablets | 2002 |
Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.
Topics: Adult; Biological Availability; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Mixed Function Oxygenases; Nelfinavir; Saquinavir; Sulfonamides | 2002 |
Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under Curve; Carbamates; Delavirdine; Drug Administration Schedule; Drug Interactions; Female; Furans; Humans; Longitudinal Studies; Male; Middle Aged; Reference Values; Sulfonamides | 2002 |
Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients.
Topics: Adult; Alkynes; Area Under Curve; Benzoxazines; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; Furans; Half-Life; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oxazines; Ritonavir; Sulfonamides | 2003 |
Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers.
Topics: Anti-HIV Agents; Carbamates; Delavirdine; Drug Interactions; Furans; Humans; Male; Prospective Studies; Sulfonamides | 2003 |
Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Topics: Adult; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Predictive Value of Tests; Ritonavir; Sulfonamides; Viral Load | 2003 |
Amprenavir in pre-treated patients: virological and immunological response in a cohort of 45 patients.
Topics: Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Prospective Studies; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load; Viremia | 2003 |
HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Furans; Genotype; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Oxazines; Salvage Therapy; Sulfonamides | 2003 |
Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; HIV-1; Humans; Male; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2003 |
Effects of didanosine formulations on the pharmacokinetics of amprenavir.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Area Under Curve; Capsules; Carbamates; Cross-Over Studies; Didanosine; Drug Interactions; Drug Therapy, Combination; Female; Furans; Humans; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Sulfonamides; Tablets, Enteric-Coated; Time Factors | 2003 |
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Enfuvirtide; Female; Furans; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Peptide Fragments; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2003 |
HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations.
Topics: Algorithms; Carbamates; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Phenotype; Prospective Studies; Sulfonamides; Treatment Outcome | 2003 |
In vitro-in vivo model for evaluating the antiviral activity of amprenavir in combination with ritonavir administered at 600 and 100 milligrams, respectively, every 12 hours.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Carbamates; Cell Line; Cells, Cultured; Drug Combinations; Female; Furans; HIV Antigens; Humans; Male; Middle Aged; Models, Biological; Protein Binding; Ritonavir; Sulfonamides; T-Lymphocytes; Tetrazolium Salts; Thiazoles; Time Factors | 2003 |
Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Area Under Curve; Carbamates; CD4 Lymphocyte Count; Cross-Over Studies; Dideoxynucleosides; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphates; RNA, Viral; Sulfonamides | 2004 |
A prospective, controlled study assessing the effect of lopinavir on amprenavir concentrations boosted by ritonavir.
Topics: Anti-HIV Agents; Carbamates; Drug Interactions; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; HIV Seropositivity; Humans; Lopinavir; Prospective Studies; Pyrimidinones; Ritonavir; Sulfonamides | 2004 |
Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens.
Topics: Adult; Antiretroviral Therapy, Highly Active; Area Under Curve; Carbamates; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Resistance, Viral; Female; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Mutation; Patient Selection; Phenotype; Predictive Value of Tests; Prospective Studies; Pyrimidinones; Ritonavir; RNA, Viral; Salvage Therapy; Sulfonamides; Treatment Outcome; Viral Load | 2004 |
Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers.
Topics: Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Carbamates; Cholesterol; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Female; Furans; Humans; Linear Models; Male; Middle Aged; Organophosphates; Oxazines; Prodrugs; Ritonavir; Sulfonamides; Triglycerides | 2004 |
Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus.
Topics: Administration, Oral; Adult; Antiretroviral Therapy, Highly Active; Biological Availability; Carbamates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Furans; HIV Infections; Humans; Lopinavir; Male; Maximum Tolerated Dose; Middle Aged; Probability; Pyrimidinones; Risk Assessment; Ritonavir; Salvage Therapy; Severity of Illness Index; Single-Blind Method; Statistics, Nonparametric; Sulfonamides; Survival Rate; Treatment Outcome; Viral Load | 2004 |
Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pilot Projects; Pyrimidinones; Ritonavir; RNA, Viral; Salvage Therapy; Sulfonamides | 2004 |
Impact of insertions in the HIV-1 p6 PTAPP region on the virological response to amprenavir.
Topics: Adult; Amino Acid Motifs; Amino Acid Sequence; Carbamates; Female; Furans; gag Gene Products, Human Immunodeficiency Virus; Gene Products, gag; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Molecular Sequence Data; Mutation; Phenotype; RNA, Viral; Sequence Analysis, DNA; Sulfonamides; Viral Load | 2004 |
Dose-dependent pharmacokinetics of delavirdine in combination with amprenavir in healthy volunteers.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Carbamates; Chromatography, High Pressure Liquid; Delavirdine; Dose-Response Relationship, Drug; Drug Combinations; Furans; Humans; Male; Prospective Studies; Spectrophotometry, Ultraviolet; Sulfonamides | 2004 |
The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir.
Topics: Adult; Carbamates; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Ritonavir; Salvage Therapy; Saquinavir; Sulfonamides; Viral Load | 2004 |
Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; Furans; HIV Infections; HIV Protease; HIV-1; Humans; Logistic Models; Male; Mutation; Prospective Studies; Salvage Therapy; Sulfonamides; Viral Load | 2004 |
A randomized study investigating the efficacy and safety of amprenavir in combination with low-dose ritonavir in protease inhibitor-experienced HIV-infected adults.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Carbamates; Female; Furans; Genes, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Ritonavir; Sulfonamides | 2004 |
A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients.
Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; Carbamates; Female; Furans; HIV Infections; Humans; Male; Middle Aged; Ritonavir; Sulfonamides | 2004 |
Changes in thrombolytic and inflammatory markers after initiation of indinavir- or amprenavir-based antiretroviral therapy.
Topics: Adult; Biomarkers; Blood Glucose; Carbamates; Drug Therapy, Combination; Female; Fibrinolysis; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Inflammation; Insulin Resistance; Male; Plasminogen Activator Inhibitor 1; Prospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Sulfonamides; Tissue Plasminogen Activator | 2004 |
Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
Topics: Adult; Aged; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; France; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; RNA, Viral; Salvage Therapy; Sulfonamides; Viral Load | 2004 |
Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Carbamates; Confidence Intervals; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Male; Methadone; Opioid-Related Disorders; Reaction Time; Stereoisomerism; Sulfonamides | 2004 |
Pharmacokinetic and pharmacodynamic analysis of amprenavir-containing combination therapy in HIV-1-infected children.
Topics: Adolescent; Anti-HIV Agents; Carbamates; Child; Child, Preschool; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Inhibitory Concentration 50; Male; Sulfonamides | 2004 |
Single-dose safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, in HIV-infected children.
Topics: Area Under Curve; Carbamates; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Sulfonamides; Treatment Outcome | 2005 |
Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir.
Topics: Aluminum Hydroxide; Antacids; Anti-Ulcer Agents; Area Under Curve; Carbamates; Drug Administration Schedule; Drug Combinations; Drug Interactions; Furans; HIV Protease Inhibitors; Humans; Magnesium Hydroxide; Organophosphates; Ranitidine; Sulfonamides | 2005 |
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
Topics: Adult; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Ritonavir; Salvage Therapy; Sulfonamides; Treatment Outcome | 2005 |
Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; HIV Seronegativity; Humans; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides | 2005 |
Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV.
Topics: Adult; Area Under Curve; Carbamates; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; Humans; Male; Middle Aged; Organophosphates; Ritonavir; Sulfonamides | 2006 |
Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Female; Furans; HIV Infections; Humans; Male; Middle Aged; Organophosphates; Prodrugs; Ritonavir; Sulfonamides | 2007 |
Salvage therapy with amprenavir, lopinavir and ritonavir is durably potent in HIV-infected patients in virological failure: 1-year results.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Drug Resistance, Multiple, Viral; Follow-Up Studies; Furans; HIV Infections; HIV-1; Humans; Lopinavir; Pyrimidinones; Ritonavir; Salvage Therapy; Sulfonamides | 2007 |
Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state.
Topics: Administration, Oral; Adult; Carbamates; Cross-Over Studies; Duodenum; Fasting; Feasibility Studies; Female; Food-Drug Interactions; Furans; Gastric Juice; HIV Protease Inhibitors; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Intestinal Secretions; Male; Organophosphates; Postprandial Period; Solubility; Sulfonamides; Tablets | 2007 |
Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged.
Topics: Adolescent; Adult; Antifungal Agents; Area Under Curve; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Organophosphates; Ritonavir; Sulfonamides; Treatment Outcome | 2007 |
Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir.
Topics: Adenine; Anti-Retroviral Agents; Area Under Curve; Carbamates; Cross-Over Studies; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; HIV Seronegativity; Humans; Male; Organophosphates; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir | 2007 |
Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Ritonavir; Sulfonamides | 2007 |
Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers.
Topics: Adult; Aged; Blood Glucose; Carbamates; Double-Blind Method; Energy Metabolism; Furans; Glucose Clamp Technique; HIV Protease Inhibitors; Humans; Indinavir; Insulin; Insulin Resistance; Lactic Acid; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Sulfonamides | 2007 |
Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen.
Topics: Adult; Aged; Carbamates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; France; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Phenotype; Prognosis; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2008 |
Saquinavir plus lopinavir/ritonavir versus amprenavir plus lopinavir/ritonavir for treating highly resistant patients in Brazil.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Pilot Projects; Prospective Studies; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Treatment Outcome | 2008 |
Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
Topics: Adult; Anti-HIV Agents; Carbamates; Cross-Over Studies; Drug Interactions; Female; Furans; Humans; Male; Methadone; Narcotics; Organophosphates; Prodrugs; Ritonavir; Stereoisomerism; Sulfonamides | 2008 |
Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
Topics: Adolescent; Adult; Aged; Atazanavir Sulfate; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; HIV Seronegativity; Humans; Male; Middle Aged; Oligopeptides; Organophosphates; Prodrugs; Pyridines; Ritonavir; Sulfonamides | 2009 |
The acute effects of HIV protease inhibitors on insulin suppression of glucose production in healthy HIV-negative men.
Topics: Carbamates; Furans; Glucose; HIV Protease Inhibitors; Human Experimentation; Humans; Indinavir; Insulin; Male; Placebos; Ritonavir; Sulfonamides | 2009 |
Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Carbamates; Cross-Over Studies; Drug Administration Schedule; Drug Eruptions; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; Humans; Male; Middle Aged; Organophosphates; Organophosphonates; Prodrugs; Ritonavir; Sulfonamides; Tenofovir; Young Adult | 2010 |
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
Topics: Adamantane; Adult; Analysis of Variance; Atazanavir Sulfate; Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Microbial Sensitivity Tests; Molecular Typing; Nelfinavir; Neuraminidase; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides; Viral Load | 2010 |
HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" study.
Topics: Aging; Atazanavir Sulfate; Carbamates; Cross-Sectional Studies; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamin Type A; Leukocytes, Mononuclear; Longitudinal Studies; Lopinavir; Male; Nuclear Proteins; Oligopeptides; Protein Precursors; Pyridines; Ritonavir; Sulfonamides; Viral Load | 2012 |
Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects.
Topics: Adult; Area Under Curve; Carbamates; Drug Administration Schedule; Drug Interactions; Female; Furans; Healthy Volunteers; Heterocyclic Compounds, 3-Ring; HIV Integrase; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Organophosphates; Oxazines; Piperazines; Pyridones; Ritonavir; Sulfonamides | 2014 |
Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients.
Topics: Adolescent; Carbamates; Child; Child, Preschool; Computer Simulation; Drug Dosage Calculations; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Male; Models, Biological; Organophosphates; Prodrugs; Ritonavir; Sulfonamides | 2014 |
The influence of gastric motility on the intraluminal behavior of fosamprenavir.
Topics: Adult; Carbamates; Cross-Over Studies; Digestion; Duodenum; Female; Furans; Gastrointestinal Agents; Gastrointestinal Motility; Humans; Male; Middle Aged; Organophosphates; Stomach; Sulfonamides; Young Adult | 2020 |
318 other study(ies) available for carbamates and amprenavir
| Article | Year |
|---|---|
Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy.
Topics: Acquired Immunodeficiency Syndrome; Animals; Antiviral Agents; Blood; Blood Proteins; Carbamates; Cattle; Fetus; Furans; HIV Protease Inhibitors; Humans; Kinetics; Molecular Structure; Orosomucoid; Protein Binding; Spectrophotometry, Ultraviolet; Sulfonamides | 1995 |
In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease.
Topics: Amino Acid Sequence; Base Sequence; Carbamates; Cell Line; DNA Primers; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Kinetics; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Molecular Structure; Mutagenesis, Site-Directed; Point Mutation; Polymerase Chain Reaction; Protein Conformation; Recombinant Proteins; Structure-Activity Relationship; Sulfonamides; T-Lymphocytes; Virus Replication | 1995 |
Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease.
Topics: Antiviral Agents; Blood Proteins; Carbamates; Clinical Trials as Topic; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Orosomucoid; Protein Binding; Sulfonamides | 1996 |
Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants.
Topics: Amino Acid Sequence; Binding Sites; Carbamates; Furans; Genetic Variation; HIV Protease; HIV Protease Inhibitors; HIV-1; Hydrolysis; Indinavir; Isoquinolines; Kinetics; Models, Molecular; Molecular Sequence Data; Mutation; Oligopeptides; Pyridines; Quinolines; Saquinavir; Selection, Genetic; Substrate Specificity; Sulfonamides | 1996 |
In vitro metabolism of a potent HIV-protease inhibitor (141W94) using rat, monkey and human liver S9.
Topics: Animals; Aroclors; Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Protease Inhibitors; Humans; In Vitro Techniques; Liver; Macaca fascicularis; Mass Spectrometry; Rats; Rats, Sprague-Dawley; Species Specificity; Spectrophotometry, Ultraviolet; Subcellular Fractions; Sulfonamides | 1996 |
Calculation of solvation and binding free energy differences between VX-478 and its analogs by free energy perturbation and AMSOL methods.
Topics: Binding Sites; Carbamates; Computer Simulation; Furans; HIV Protease; HIV Protease Inhibitors; Models, Molecular; Molecular Structure; Software; Solvents; Sulfonamides; Thermodynamics; Water | 1996 |
Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity.
Topics: Carbamates; Clinical Trials as Topic; Furans; Fusion Proteins, gag-pol; HIV Protease; HIV Protease Inhibitors; Humans; Hydrolysis; Indinavir; Kinetics; Mutagenesis; Ritonavir; Sulfonamides | 1996 |
Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Microbial; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Kinetics; Mutagenesis; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; Sulfonic Acids | 1996 |
In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors.
Topics: Anti-HIV Agents; Carbamates; Cell Line; Cells, Cultured; Ethylenes; Furans; HIV Protease Inhibitors; HIV Seronegativity; HIV-1; Humans; Indinavir; Kinetics; Lymphocytes; Orosomucoid; Ritonavir; Saquinavir; Sulfonamides; Urea; Virus Replication | 1997 |
A molecular field-based similarity approach to pharmacophoric pattern recognition.
Topics: Carbamates; Computer Graphics; Furans; HIV Protease; HIV Protease Inhibitors; Models, Molecular; Molecular Structure; Oligopeptides; Pattern Recognition, Automated; Sugar Alcohols; Sulfonamides; Valine | 1997 |
A computational study of the resistance of HIV-1 aspartic protease to the inhibitors ABT-538 and VX-478 and design of new analogues.
Topics: Binding Sites; Carbamates; Computer Simulation; Drug Design; Drug Resistance; Furans; HIV Protease; HIV Protease Inhibitors; Models, Molecular; Molecular Conformation; Mutagenesis, Site-Directed; Protein Binding; Ritonavir; Sulfonamides | 1998 |
Practical synthesis of (2s,3s)-3-amino-2-hydroxy-4-phenylbutyric acid, a key component of HIV protease inhibitors.
Topics: Anti-HIV Agents; Carbamates; Furans; HIV Protease Inhibitors; Nitriles; Oligopeptides; Phenylbutyrates; Stereoisomerism; Sulfonamides | 1998 |
Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions.
Topics: Anti-HIV Agents; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Furans; HIV Protease Inhibitors; Humans; Isoenzymes; Microsomes, Liver; Mixed Function Oxygenases; Ritonavir; Saquinavir; Sulfonamides | 1998 |
Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy.
Topics: Adult; Aged; Anti-HIV Agents; Carbamates; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Division; Dideoxynucleosides; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Ki-67 Antigen; Lymph Nodes; Male; Middle Aged; Reverse Transcriptase Inhibitors; Sulfonamides | 1998 |
Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro.
Topics: Anti-HIV Agents; Carbamates; Cell Line; Dideoxynucleosides; Drug Synergism; Furans; HIV Protease Inhibitors; HIV-1; Humans; Sulfonamides | 1998 |
HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy.
Topics: Amino Acid Substitution; Carbamates; Clinical Trials as Topic; Databases, Factual; DNA, Viral; Furans; Genetic Linkage; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Methionine; Nelfinavir; Phenotype; Polymerase Chain Reaction; Ritonavir; Saquinavir; Sulfonamides; Valine | 1998 |
Phase III results of second-generation HIV protease inhibitor reported.
Topics: Anti-HIV Agents; Carbamates; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Sulfonamides; Viral Load; Zidovudine | 1998 |
The ex vivo human placental transfer of the anti-HIV nucleoside inhibitor abacavir and the protease inhibitor amprenavir.
Topics: Carbamates; Dideoxynucleosides; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; In Vitro Techniques; Maternal-Fetal Exchange; Placenta; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Sulfonamides | 1998 |
Updated data on amprenavir.
Topics: Adult; Carbamates; Child; Clinical Trials as Topic; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Male; Semen; Sulfonamides; Viral Load | 1999 |
Salvage therapy with ritonavir-saquinavir plus two nucleoside reverse transcriptase inhibitors in patients failing with amprenavir-zidovudine-lamivudine.
Topics: Adult; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Salvage Therapy; Saquinavir; Sulfonamides; Zidovudine | 1999 |
Amprenavir approved for HIV treatment.
Topics: Adolescent; Adult; Anti-HIV Agents; Carbamates; Child; Child, Preschool; Drug Approval; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; United States; United States Food and Drug Administration | 1999 |
Amprenavir: a new HIV protease inhibitor.
Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Carbamates; Child; Clinical Trials as Topic; Cross Reactions; Diarrhea; Drug Administration Schedule; Drug Interactions; Drug Resistance, Microbial; Exanthema; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Nausea; Stevens-Johnson Syndrome; Sulfonamides | 1999 |
Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autoradiography; Biological Transport; Caco-2 Cells; Carbamates; Cattle; Central Nervous System; Drug Interactions; Furans; HIV Protease Inhibitors; Humans; Male; Mice; Mice, Knockout; Ritonavir; Sulfonamides; Whole-Body Irradiation | 1999 |
Inhibition of adipocyte differentiation by HIV protease inhibitors.
Topics: 3T3 Cells; Adipocytes; Adiponectin; Animals; Carbamates; Carrier Proteins; Cell Differentiation; Dose-Response Relationship, Drug; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Furans; Gene Expression; Glycoproteins; HIV Protease Inhibitors; Humans; Indinavir; Intercellular Signaling Peptides and Proteins; Lipoprotein Lipase; Mice; Myelin P2 Protein; Nelfinavir; Neoplasm Proteins; Nerve Tissue Proteins; Proteins; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Ritonavir; Stem Cells; Sulfonamides; Transcription Factors; Triglycerides; Tumor Suppressor Proteins | 1999 |
Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability.
Topics: Algorithms; Animals; Biological Availability; Caco-2 Cells; Calcium Channel Blockers; Carbamates; Cell Membrane Permeability; Chromatography, High Pressure Liquid; Dogs; Furans; HIV Protease Inhibitors; Humans; Permeability; Polyethylene Glycols; Solubility; Stimulation, Chemical; Sulfonamides; Verapamil; Vitamin E | 1999 |
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; Dideoxynucleosides; Furans; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Lymph Nodes; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Stavudine; Sulfonamides; Time Factors; Viral Load; Viremia; Zidovudine | 2000 |
Amprenavir study results released.
Topics: Anti-HIV Agents; Carbamates; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Sulfonamides; Viral Load; Zidovudine | 1999 |
A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir.
Topics: Anti-HIV Agents; Carbamates; Drug Hypersensitivity; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Mutagenesis, Site-Directed; Sulfonamides | 2000 |
When to switch and what to switch to: strategic use of antiretroviral therapy.
Topics: Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Microbial Sensitivity Tests; Mutation; Nelfinavir; Practice Guidelines as Topic; Pyrimidinones; Retroviridae; Retroviridae Infections; Reverse Transcriptase Inhibitors; Sulfonamides; Time Factors; Treatment Failure; Viral Load | 2000 |
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction.
Topics: Alkynes; Benzoxazines; Calibration; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Stability; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Oxazines; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides | 2000 |
Metabolic profile of protease inhibitors studied.
Topics: Adipose Tissue; Animals; Carbamates; Disease Models, Animal; Furans; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Hyperglycemia; Hyperlipidemias; Lipid Metabolism; Mice; Randomized Controlled Trials as Topic; Retrospective Studies; Sulfonamides | 1999 |
Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir.
Topics: Anti-HIV Agents; Carbamates; Computer Simulation; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Furans; Humans; Monte Carlo Method; Sulfonamides | 2000 |
[Second chance therapy. New protease inhibitor for salvage therapy].
Topics: Carbamates; Drug Therapy, Combination; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Salvage Therapy; Sulfonamides; Treatment Outcome | 2000 |
Amprenavir approved.
Topics: Anti-HIV Agents; Carbamates; Controlled Clinical Trials as Topic; Drug Approval; Drug Therapy, Combination; Female; Follow-Up Studies; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Sulfonamides; Treatment Outcome; United States; United States Food and Drug Administration | 1999 |
Sensitive liquid chromatographic assay for amprenavir, a human immunodeficiency virus protease inhibitor, in human plasma, cerebrospinal fluid and semen.
Topics: Adult; Anti-HIV Agents; Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Protease Inhibitors; Humans; Male; Reproducibility of Results; Semen; Sensitivity and Specificity; Spectrometry, Fluorescence; Sulfonamides | 2000 |
Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture.
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamates; Cell Line, Transformed; Colonic Neoplasms; Drug Resistance, Multiple; Furans; Gene Expression Regulation, Neoplastic; HIV Protease Inhibitors; Humans; Indinavir; Ivermectin; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; Tumor Cells, Cultured; Verapamil; Vinblastine | 2000 |
Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir.
Topics: Carbamates; Crystallography, X-Ray; Drug Resistance, Microbial; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Kinetics; Models, Molecular; Mutation; Protein Conformation; Saquinavir; Sulfonamides | 2000 |
Mutation causes sensitivity.
Topics: Carbamates; Drug Resistance, Microbial; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Sulfonamides | 2000 |
Simultaneous determination of the five HIV-protease inhibitors: amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by solid-phase extraction and column liquid chromatography.
Topics: Carbamates; Chromatography, Liquid; Drug Monitoring; Furans; HIV Protease Inhibitors; Humans; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2000 |
The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection.
Topics: Anti-HIV Agents; Carbamates; Dideoxynucleosides; Furans; HIV Antibodies; HIV Core Protein p24; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Lamivudine; Neutralization Tests; Ritonavir; Sulfonamides; Zidovudine | 2000 |
Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole.
Topics: Aryl Hydrocarbon Hydroxylases; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Furans; Humans; Hydroxylation; Ketoconazole; Oxidoreductases, N-Demethylating; Ritonavir; Sulfonamides; Triazolam | 2000 |
Dietary fat alters HIV protease inhibitor-induced metabolic changes in mice.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Carbamates; Dietary Fats; Drug Interactions; Furans; HIV Protease Inhibitors; Indinavir; Injections, Subcutaneous; Insulin; Liver; Male; Mice; Mice, Inbred AKR; Nelfinavir; Saquinavir; Sulfonamides | 2000 |
Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group.
Topics: Amino Acid Sequence; Amino Acid Substitution; Carbamates; Codon; Drug Resistance, Microbial; Furans; Global Health; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Molecular Sequence Data; Mutation; Nelfinavir; Phylogeny; Ritonavir; Saquinavir; Sulfonamides | 2000 |
Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Child; Child, Preschool; Cyclopropanes; Delavirdine; Drug Interactions; Drug Therapy, Combination; Furans; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides; Time Factors | 2000 |
HIV protease inhibitors block adipogenesis and increase lipolysis in vitro.
Topics: Adipocytes; Animals; Azo Compounds; Bexarotene; Carbamates; Carrier Proteins; Cell Differentiation; Cells, Cultured; Coloring Agents; Fatty Acid-Binding Proteins; Furans; HIV Protease Inhibitors; Indinavir; Insulin; Lipolysis; Lipoprotein Lipase; Nelfinavir; Neoplasm Proteins; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Ritonavir; RNA, Messenger; Rosiglitazone; Saquinavir; Stem Cells; Sulfonamides; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2000 |
Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir.
Topics: Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Carbamates; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Drug Therapy, Combination; Furans; HIV Infections; Humans; Oxazines; Oxidoreductases, N-Demethylating; Ritonavir; Sulfonamides | 2000 |
Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors.
Topics: Carbamates; Drug Resistance, Microbial; Drug Resistance, Multiple; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Ritonavir; Saquinavir; Sulfonamides | 2000 |
Warning for oral solution.
Topics: Administration, Oral; Carbamates; Chemistry, Pharmaceutical; Drug Labeling; Furans; HIV Protease Inhibitors; Humans; Intestinal Absorption; Pharmaceutical Vehicles; Propylene Glycol; Solutions; Sulfonamides | 2000 |
Pharmacology and clinical experience with amprenavir.
Topics: Animals; Antiretroviral Therapy, Highly Active; Carbamates; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Microbial; Furans; HIV Protease Inhibitors; Humans; Sulfonamides | 2000 |
[Hyperlipoproteineumia in HIV patients undergoing antiretroviral therapy: which risk is greater--pancreatitis or coronary disease?].
Topics: Acquired Immunodeficiency Syndrome; Acute Disease; Anti-HIV Agents; Carbamates; Coronary Disease; Dideoxynucleosides; Drug Therapy, Combination; Furans; Hepatitis B; HIV Protease Inhibitors; Humans; Hyperlipoproteinemias; Male; Middle Aged; Pancreatitis; Risk Factors; Ritonavir; Sulfonamides | 2000 |
The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds.
Topics: Acetamides; Albumins; Azepines; Caco-2 Cells; Carbamates; Cell Membrane Permeability; Furans; HIV Protease Inhibitors; Humans; Indinavir; Intestinal Absorption; Nelfinavir; Ritonavir; Solvents; Structure-Activity Relationship; Sulfonamides; Urea | 2000 |
Raising levels of amprenavi.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Cyclopropanes; Drug Interactions; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Viral Load | 2000 |
Increased turnover of CCR5+ and redistribution of CCR5- CD4 T lymphocytes during primary human immunodeficiency virus type 1 infection.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Dideoxynucleosides; Epstein-Barr Virus Infections; Flow Cytometry; Furans; Genotype; HIV Infections; HIV-1; Humans; Immunoglobulin M; Lamivudine; Longitudinal Studies; Male; Proto-Oncogene Proteins c-bcl-2; Receptors, CCR5; Sulfonamides; Time Factors; Zidovudine | 2001 |
Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.
Topics: Animals; Astrocytes; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Transport, Active; Blood-Brain Barrier; Caco-2 Cells; Carbamates; Cattle; Cell Line, Transformed; Cells, Cultured; Coculture Techniques; Cyclosporins; Dibenzocycloheptenes; Endothelium, Vascular; Furans; HIV Protease Inhibitors; Humans; Indinavir; LLC-PK1 Cells; Multidrug Resistance-Associated Proteins; Probenecid; Quinolines; Rats; Rats, Wistar; Ritonavir; Sulfonamides; Swine; Verapamil | 2001 |
Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.
Topics: Animals; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Furans; HIV Protease Inhibitors; Humans; Intestinal Mucosa; Intestines; Liver; Male; Nelfinavir; Oxidoreductases, N-Demethylating; Rats; Rats, Wistar; Sulfonamides; Tumor Cells, Cultured | 2001 |
Phase III trials for new PI.
Topics: Antiretroviral Therapy, Highly Active; Carbamates; Chemistry, Pharmaceutical; Clinical Trials, Phase III as Topic; Dideoxynucleosides; Furans; HIV Protease Inhibitors; Humans; Lamivudine; Multicenter Studies as Topic; Nelfinavir; Organophosphates; Prodrugs; Randomized Controlled Trials as Topic; Sulfonamides | 2001 |
Effect of reduced-dose amprenavir in combination with lopinavir on plasma levels of amprenavir in patients infected with HIV.
Topics: Adult; Carbamates; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Sulfonamides | 2001 |
Liquid chromatographic-tandem mass spectrometric determination of amprenavir (agenerase) in serum/plasma of human immunodeficiency virus type-1 infected patients receiving combination antiretroviral therapy.
Topics: Anti-HIV Agents; Carbamates; Chromatography, Liquid; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Mass Spectrometry; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Sulfonamides | 2001 |
Abacavir (1592) with protease inhibitors in potent antiretroviral activity.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Carbamates; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; Viral Load | 1998 |
Double protease inhibitor regimens with amprenavir show promise.
Topics: Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Saquinavir; Sulfonamides; Viral Load; Zidovudine | 1998 |
Amprenavir made available through early access program.
Topics: Anti-HIV Agents; Carbamates; Drug Approval; Furans; Health Services Accessibility; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; United States | 1998 |
NDA submitted for amprenavir.
Topics: Carbamates; Furans; HIV Protease Inhibitors; Humans; Investigational New Drug Application; Sulfonamides | 1999 |
Agenerase shows promise in treatment-naïve and treatment-experienced HIV patients.
Topics: Carbamates; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Sulfonamides | 1999 |
Protease inhibitors and prevention of cross resistance.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Carbamates; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Lamivudine; Nelfinavir; Pyridines; Quinolines; Saquinavir; Sulfonamides; Zalcitabine; Zidovudine | 1995 |
New protease drug shows early promise.
Topics: Antiviral Agents; Carbamates; Clinical Trials, Phase I as Topic; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Furans; HIV; HIV Protease Inhibitors; Humans; Sulfonamides | 1995 |
Conference looks at HIV drug resistance.
Topics: Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Lamivudine; Pyridines; Quinolines; Ritonavir; Saquinavir; Sulfonamides; Thiazoles; Valine; Viremia; Zalcitabine; Zidovudine | 1995 |
ICAAC update.
Topics: Acetamides; Acetophenones; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides; Viral Load | 1996 |
Pediatric trial of 141W94, Vertex protease inhibitor.
Topics: Adolescent; Anti-HIV Agents; Carbamates; Child; Child, Preschool; Clinical Trials, Phase III as Topic; Furans; HIV Infections; Humans; Infant; Patient Selection; Sulfonamides; United States; Viral Load | 1997 |
141 (Vertex-478).
Topics: Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Sulfonamides; Viral Load; Zidovudine | 1997 |
Expanded access to experimental drugs: activists seek more open programs.
Topics: Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Dideoxynucleosides; Drug Industry; Furans; Health Services Accessibility; HIV Protease Inhibitors; Humans; Reverse Transcriptase Inhibitors; Sulfonamides | 1997 |
Protease inhibitor failure trial: combination 1592, 141W94, and efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials, Phase II as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Male; Multicenter Studies as Topic; Oxazines; Patient Selection; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Failure | 1997 |
What's new and what's next.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-2; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides | 1998 |
Selected highlights from the 5th Conference on Retroviruses and Opportunistic Infections.
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Carbamates; Chicago; Clinical Trials as Topic; Congresses as Topic; Cyclopropanes; Dideoxynucleosides; Drug Hypersensitivity; Drug Interactions; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxyurea; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides | 1998 |
New drugs: amprenavir and abacavir.
Topics: Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Sulfonamides; Viral Load; Zidovudine | 1998 |
What's new, what's next?
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Carbamates; Decision Making; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxyurea; Patient Compliance; Saquinavir; Sulfonamides | 1998 |
New drugs on the horizon.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides; United States; Zidovudine | 1998 |
New drugs in development.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Imidazoles; Kidney Diseases; Lopinavir; Oxazines; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Sulfonamides; Viral Load | 1998 |
Amprenavir (Agenerase) now available in expanded access.
Topics: Adolescent; Adult; Carbamates; Child; Child, Preschool; Clinical Trials as Topic; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides | 1998 |
Access to efavirenz and amprenavir.
Topics: Alkynes; Benzoxazines; Carbamates; Cyclopropanes; Furans; Health Services Accessibility; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides; United States | 1998 |
Expanded access program begins.
Topics: Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Patient Selection; Sulfonamides; United States | 1998 |
Glaxo Wellcome's two new drugs.
Topics: Anti-HIV Agents; Carbamates; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides | 1998 |
What's new, what's next?
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides | 1999 |
Retrovirus conference report: three new agents to the rescue.
Topics: Anti-HIV Agents; Carbamates; Congresses as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; Drugs, Investigational; Enfuvirtide; Furans; HIV Envelope Protein gp41; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Peptide Fragments; Pyrimidinones; Salvage Therapy; Sulfonamides; Viral Load; Virus Replication | 1999 |
Antimicrobial agents and chemotherapy: highlights of the 38th Interscience Conference.
Topics: Adenine; Antiviral Agents; Bacterial Vaccines; Carbamates; Congresses as Topic; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Pneumococcal Infections; Sulfonamides; Vaccination; Viral Load | 1998 |
The new drugs and how to use them.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Sulfonamides | 1999 |
Some existing drugs work on resistant HIV.
Topics: Anti-HIV Agents; Carbamates; Dioxolanes; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Purine Nucleosides; Pyridines; Pyrones; Sulfonamides | 2000 |
Study: new drug doesn't display cross-resistance.
Topics: Carbamates; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Mutation; Salvage Therapy; Sulfonamides | 1999 |
Amprenavir, new protease inhibitor, approved.
Topics: Adolescent; Adult; Carbamates; Child; Child, Preschool; Drug Approval; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; United States Food and Drug Administration | 1999 |
Expanded access.
Topics: Adenine; Anti-HIV Agents; Carbamates; Dideoxynucleosides; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides | 1998 |
Antivirals update.
Topics: Anti-HIV Agents; Carbamates; Delavirdine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nevirapine; Reverse Transcriptase Inhibitors; Salvage Therapy; Sulfonamides | 1998 |
Drug approval.
Topics: Carbamates; Drug Approval; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; United States; United States Food and Drug Administration | 1999 |
Amprenavir (Agenerase) receives FDA approval. Food and Drug Administration.
Topics: Carbamates; Drug Approval; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; United States; United States Food and Drug Administration | 1999 |
Amprenavir (Agenerase).
Topics: Biological Availability; Carbamates; Clinical Trials as Topic; Diet; Drug Interactions; Drug Resistance, Microbial; Drug Storage; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Pharmacokinetics; Sulfonamides | 1999 |
Expanded access.
Topics: Adenine; Anti-HIV Agents; Carbamates; Drug Approval; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Failure; United States; United States Food and Drug Administration | 1999 |
Amprenavir approved.
Topics: Anti-HIV Agents; Carbamates; Drug Approval; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; United States; United States Food and Drug Administration | 1999 |
New treatment options.
Topics: Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Reverse Transcriptase Inhibitors; Sulfonamides; Viral Load | 1999 |
Antiretroviral update from the Interscience Conference on Antimicrobial Agents and Chemotherapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides | 1998 |
New expanded access drugs for use in combination therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Child; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Male; Pregnancy; Sulfonamides | 1998 |
Amprenavir: a new protease inhibitor nears approval.
Topics: Anti-HIV Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Approval; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Sulfonamides | 1999 |
New anti-HIV drugs in development.
Topics: Adverse Drug Reaction Reporting Systems; Anti-HIV Agents; Capsules; Carbamates; Chemistry, Pharmaceutical; Didanosine; Drug Synergism; Drug Therapy, Combination; Drugs, Investigational; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Menorrhagia; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides | 1999 |
Novel approaches for the treatment of HIV.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; Genetic Therapy; Heterocyclic Compounds; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Oxazines; Receptors, Chemokine; Reverse Transcriptase Inhibitors; Sulfonamides; Zinc Fingers | 1998 |
Fifth Conference on Retroviruses & Opportunistic Infections. Interview by Ron Baker.
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Congresses as Topic; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Drugs, Investigational; Furans; Genetic Techniques; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxyurea; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides; Viral Load | 1998 |
Moving forward: a treatment overview from the 12th World AIDS Conference.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4-Positive T-Lymphocytes; Clinical Trials as Topic; Congresses as Topic; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Furans; Health Services Accessibility; HIV Protease Inhibitors; Humans; Hydroxyurea; Lopinavir; Oxazines; Patient Care Planning; Pyrimidinones; Remission Induction; Reverse Transcriptase Inhibitors; Sulfonamides; Switzerland; Virus Replication | 1998 |
[Determining resistance in HIV therapy. Careful interpretation only].
Topics: Anti-HIV Agents; Carbamates; Dideoxynucleosides; Drug Resistance, Microbial; Furans; HIV; HIV Infections; Humans; Mutation; Sulfonamides | 2001 |
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography.
Topics: Adult; Calibration; Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2001 |
Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography.
Topics: Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Reference Standards; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfonamides | 2001 |
Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay.
Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, Liquid; Cyclopropanes; Delavirdine; Drug Monitoring; Furans; HIV Protease Inhibitors; Humans; Indinavir; Mass Spectrometry; Nelfinavir; Nevirapine; Oxazines; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides | 2001 |
High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid e
Topics: Calibration; Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Nevirapine; Reference Standards; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides | 2001 |
Drifting agenda for federal treatment research.
Topics: Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Dideoxynucleosides; Drug Therapy, Combination; Financing, Government; Furans; HIV Infections; HIV Protease Inhibitors; National Institutes of Health (U.S.); Reverse Transcriptase Inhibitors; Sulfonamides; United States | 2001 |
Effectors of HIV-1 protease peptidolytic activity.
Topics: Carbamates; DNA; Drug Interactions; Enzyme Activation; Fluorescent Dyes; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Hydrolysis; Kinetics; Ligands; Models, Chemical; Oligopeptides; Poly A; Polyelectrolytes; Polymers; Sodium Chloride; Sulfonamides | 2001 |
Amping amprenavir with ritonavir.
Topics: Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir; Sulfonamides; Viral Load | 2001 |
Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir.
Topics: Acquired Immunodeficiency Syndrome; Analgesics, Opioid; Carbamates; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; HIV-1; Humans; Methadone; Reverse Transcriptase Inhibitors; Substance-Related Disorders; Sulfonamides | 2001 |
Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC.
Topics: Carbamates; Chromatography, High Pressure Liquid; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Pyrimidinones; Reproducibility of Results; Ritonavir; Saquinavir; Sulfonamides | 2001 |
Resistant to everything.
Topics: Aged; Carbamates; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; Humans; Lopinavir; Male; Patient Compliance; Pyrimidinones; Ritonavir; Stavudine; Sulfonamides; Viral Load | 2001 |
Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD4 Lymphocyte Count; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nevirapine; Pyrimidinones; Reverse Transcriptase Inhibitors; Sulfonamides; Viral Load | 2001 |
Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo.
Topics: Adult; Amino Acid Substitution; Carbamates; Drug Resistance, Microbial; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Mutation; Sulfonamides; Viral Load | 2001 |
Amprenavir (Agenerase).
Topics: Carbamates; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Practice Guidelines as Topic; Sulfonamides | 2000 |
In vitro activity of amprenavir against Pneumocystis carinii.
Topics: Animals; Antibiotics, Antitubercular; Carbamates; Cell Line; Dose-Response Relationship, Drug; Furans; Humans; Models, Animal; Pneumocystis; Rats; Sulfonamides | 2001 |
Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors.
Topics: Amino Acid Sequence; Amino Acid Substitution; Anti-HIV Agents; Carbamates; Cell Line; Cloning, Molecular; Drug Resistance, Microbial; Furans; Gene Products, gag; HIV Protease Inhibitors; HIV-1; Humans; Molecular Sequence Data; Recombinant Proteins; Restriction Mapping; Sulfonamides | 2002 |
Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Drug Therapy, Combination; Furans; HIV; HIV Infections; Humans; Ritonavir; RNA, Viral; Sulfonamides | 2002 |
Unfavourable interaction of amprenavir and lopinavir in combination with ritonavir?
Topics: Carbamates; Drug Synergism; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Pilot Projects; Pyrimidinones; Ritonavir; Sulfonamides | 2002 |
Central nervous system toxicity and amprenavir oral solution.
Topics: Carbamates; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Neurotoxicity Syndromes; Sulfonamides | 2002 |
Determination of amprenavir, a HIV-1 protease inhibitor, in human seminal plasma using high-performance liquid chromatography-tandem mass spectrometry.
Topics: Calibration; Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Protease Inhibitors; HIV-1; Humans; Male; Mass Spectrometry; Reference Standards; Reproducibility of Results; Semen; Sensitivity and Specificity; Sulfonamides | 2002 |
In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
Topics: Administration, Oral; Animals; Area Under Curve; Biological Availability; Carbamates; Chromatography, High Pressure Liquid; Drug Interactions; Furans; HIV Protease Inhibitors; In Vitro Techniques; Indinavir; Male; Microsomes, Liver; Nelfinavir; Rats; Rats, Wistar; Saquinavir; Sulfonamides; Time Factors | 2002 |
[Advances in the domain of HIV].
Topics: Anti-HIV Agents; Blood; Carbamates; Cerebrospinal Fluid; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; Genitalia; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Mutation; Phenotype; Randomized Controlled Trials as Topic; Retrospective Studies; Ritonavir; Sulfonamides; Time Factors; Viral Load | 2002 |
Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection.
Topics: Adult; Anti-HIV Agents; Antigens, CD; Antiretroviral Therapy, Highly Active; Biomarkers; Carbamates; CD48 Antigen; CD8-Positive T-Lymphocytes; Dideoxynucleosides; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lymphocyte Count; Male; Middle Aged; Reverse Transcriptase Inhibitors; Sulfonamides; T-Lymphocyte Subsets; Treatment Outcome; Viral Load; Viremia; Zidovudine | 2002 |
Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-
Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, Liquid; Cyclopropanes; Drug Monitoring; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oxazines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides | 2002 |
Select HIV protease inhibitors alter bone and fat metabolism ex vivo.
Topics: Adipocytes; Animals; Animals, Newborn; Bone and Bones; Calcium; Carbamates; Cells, Cultured; Down-Regulation; Fats; Furans; Glycoproteins; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Mesoderm; Nelfinavir; Osteoblasts; Osteoclasts; Osteoprotegerin; Pyrimidinones; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Ritonavir; Saquinavir; Skull; Stem Cells; Sulfonamides | 2002 |
Prevalence of the HIV protease mutation N88S causing hypersensitivity to amprenavir.
Topics: Amino Acid Substitution; Anti-HIV Agents; Asparagine; Carbamates; Drug Hypersensitivity; Furans; Gene Frequency; HIV; HIV Protease; Humans; Mutation; Serine; Sulfonamides | 2002 |
Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.
Topics: Carbamates; Codon; Drug Resistance, Multiple, Viral; Furans; Genes, gag; HIV Protease; HIV Protease Inhibitors; HIV-1; Lopinavir; Mutation; Phenotype; Pyrimidinones; Recombination, Genetic; Sulfonamides; Virus Replication | 2002 |
Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy.
Topics: Carbamates; Dose-Response Relationship, Drug; Drug Interactions; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir; Salvage Therapy; Sulfonamides | 2002 |
Delavirdine increases drug exposure of ritonavir-boosted protease inhibitors.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Delavirdine; Drug Synergism; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides | 2002 |
The utility of inhibitory quotients in determining the relative potency of protease inhibitors.
Topics: Carbamates; Drug Evaluation; Furans; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2002 |
FDA approves new dosing for amprenavir and ritonavir combination.
Topics: Carbamates; Drug Approval; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir; Sulfonamides; United States; United States Food and Drug Administration | 2002 |
New dosing regimen approved.
Topics: Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir; Sulfonamides | 2002 |
High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma.
Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Monitoring; Furans; HIV Infections; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oxazines; Protease Inhibitors; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides | 2002 |
Lipodystrophy update.
Topics: Carbamates; Furans; Growth Hormone; HIV Infections; Humans; Lipodystrophy; Reverse Transcriptase Inhibitors; Sulfonamides; Surgery, Plastic | 2002 |
GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats.
Topics: Acridines; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Brain; Carbamates; Furans; HIV Protease Inhibitors; Isoquinolines; Microdialysis; Sulfonamides; Tetrahydroisoquinolines | 2002 |
Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
Topics: Binding Sites; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Furans; gag Gene Products, Human Immunodeficiency Virus; Gene Products, gag; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Substrate Specificity; Sulfonamides; Virus Replication | 2002 |
Synthesis and antiviral activity of new anti-HIV amprenavir bioisosteres.
Topics: Anti-HIV Agents; Carbamates; Cell Line; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Stereoisomerism; Structure-Activity Relationship; Sulfonamides; Virus Replication | 2002 |
Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.
Topics: Binding Sites; Calorimetry; Carbamates; Drug Design; Drug Resistance, Viral; Escherichia coli; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Kinetics; Models, Molecular; Mutagenesis, Site-Directed; Protein Binding; Sulfonamides; Thermodynamics; Urethane | 2002 |
Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Carbamates; Drug Administration Schedule; Female; Furans; Glucose; HIV Infections; Humans; Lipid Metabolism; Male; Pilot Projects; Prospective Studies; Sulfonamides | 2002 |
Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor ab
Topics: Carbamates; Cell Line; Coculture Techniques; Drug Resistance, Viral; Furans; Gene Products, gag; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Nelfinavir; Protein Precursors; Sulfonamides; Virus Replication | 2002 |
Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.
Topics: Animals; Area Under Curve; Carbamates; Drug Interactions; Drug Therapy, Combination; Furans; Half-Life; HIV Protease Inhibitors; Indinavir; Intestinal Mucosa; Liver; Male; Microsomes, Liver; Nelfinavir; Rats; Rats, Wistar; Saquinavir; Sulfonamides | 2002 |
Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites.
Topics: Amino Acid Sequence; Amino Acid Substitution; Azepines; Binding Sites; Carbamates; Catalysis; Drug Resistance, Viral; Furans; Gene Products, gag; Genes, gag; HIV Protease; HIV Protease Inhibitors; HIV-1; Kinetics; Models, Molecular; Molecular Sequence Data; Oligopeptides; Polymorphism, Genetic; Protein Conformation; Substrate Specificity; Sulfonamides; Urea | 2002 |
Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men.
Topics: Adult; Anti-HIV Agents; Carbamates; Chemistry, Pharmaceutical; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Organophosphates; Prodrugs; Ritonavir; Semen; Sulfonamides | 2002 |
Cushing's syndrome mimicking lipodystrophy syndrome in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Carbamates; Cushing Syndrome; Diagnosis, Differential; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Lipodystrophy; Male; Megestrol Acetate; Reverse Transcriptase Inhibitors; Sulfonamides | 2002 |
Pharmacokinetic interaction between lopinavir/r and amprenavir in salvage therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Carbamates; Drug Interactions; Female; Furans; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Retrospective Studies; Salvage Therapy; Sulfonamides | 2002 |
Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS.
Topics: Carbamates; Chromatography, Liquid; Furans; Gas Chromatography-Mass Spectrometry; HIV Protease Inhibitors; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides | 2002 |
Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information.
Topics: Adenine; Anti-HIV Agents; Carbamates; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Phenotype; Reverse Transcriptase Inhibitors; Sulfonamides; Tenofovir; Zalcitabine | 2002 |
Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
Topics: Carbamates; Cross-Sectional Studies; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Mutation; Phenotype; Pyrimidinones; Retrospective Studies; RNA, Viral; Sulfonamides; Viremia | 2002 |
FDA notifications. Agenerase product label changed.
Topics: Carbamates; Contraceptives, Oral, Hormonal; Drug Interactions; Drug Labeling; Furans; HIV Protease Inhibitors; Humans; Methadone; Sulfonamides; United States; United States Food and Drug Administration | 2002 |
Using Agenerase. Nutritional considerations affect bioavailability of new P.I.
Topics: Biological Availability; Carbamates; Dietary Fats; Food-Drug Interactions; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; Vitamin E | 1999 |
Agenerase approved by FDA.
Topics: Carbamates; Drug Administration Schedule; Drug Approval; Drug Resistance, Viral; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; United States; United States Food and Drug Administration | 1999 |
Effect of indinavir on the intestinal exsorption of amprenavir, saquinavir and nelfinavir after intravenous administration in rats.
Topics: Animals; Carbamates; Drug Interactions; Furans; Indinavir; Infusions, Intravenous; Intestinal Absorption; Male; Microsomes, Liver; Nelfinavir; Rats; Rats, Wistar; Saquinavir; Sulfonamides | 2003 |
Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation.
Topics: Adult; Carbamates; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Fetus; Furans; Humans; Infant; Infant, Newborn; Liver; Microsomes, Liver; Oxidation-Reduction; Protein Processing, Post-Translational; Sulfonamides | 2003 |
Effect of antimycotic agents on the activity of aspartyl proteinases secreted by Candida albicans.
Topics: Antifungal Agents; Aspartic Acid Endopeptidases; Candida albicans; Carbamates; Cell Adhesion; Dose-Response Relationship, Drug; Furans; HIV Protease Inhibitors; Saquinavir; Sulfonamides | 2003 |
Evaluation of antiretroviral drug measurements by an interlaboratory quality control program.
Topics: Alkynes; Australia; Benzoxazines; Canada; Carbamates; Cyclopropanes; Europe; Furans; HIV Protease Inhibitors; Humans; International Cooperation; Laboratories; Lopinavir; Nevirapine; Oxazines; Pyrimidinones; Quality Control; Reference Standards; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sulfonamides; United States | 2003 |
Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance.
Topics: Algorithms; Carbamates; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation; Phenotype; Pyrimidinones; Sulfonamides | 2003 |
Genotype-phenotype discordance: the evolution in our understanding HIV-1 drug resistance.
Topics: Anti-HIV Agents; Carbamates; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Phenotype; Pyrimidinones; Sulfonamides | 2003 |
Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; Heparin; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oxazines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides | 2003 |
Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples.
Topics: Atazanavir Sulfate; Carbamates; Drug Resistance, Multiple, Viral; Furans; HIV; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Retrospective Studies; Sulfonamides | 2003 |
The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates.
Topics: Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Drug Resistance, Viral; Furans; Genes, Viral; HIV-1; Humans; Molecular Sequence Data; Oxazines; Phenotype; RNA-Directed DNA Polymerase; Sulfonamides | 2003 |
HIV protease inhibitors acutely impair glucose-stimulated insulin release.
Topics: Animals; Carbamates; Cells, Cultured; Furans; Glucose; HIV Protease Inhibitors; Indinavir; Insulin; Insulin Secretion; Islets of Langerhans; Kinetics; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Nelfinavir; Ritonavir; Sulfonamides | 2003 |
Novel prodrug approach to amprenavir-based HIV-1 protease inhibitors via O-->N acyloxy migration of P1 moiety.
Topics: Carbamates; Chemical Phenomena; Chemistry, Physical; Furans; HIV Protease Inhibitors; HIV-1; Hydrogen-Ion Concentration; Indicators and Reagents; Kinetics; Magnetic Resonance Spectroscopy; Prodrugs; Solubility; Structure-Activity Relationship; Sulfonamides | 2003 |
Amprenavir (AGENERASE) oral solution: warning for some patients.
Topics: Administration, Oral; Carbamates; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Solutions; Sulfonamides | 2000 |
Fatal lactic acidosis and mimicking Guillain-Barré syndrome in an adolescent with human immunodeficiency virus infection.
Topics: Acidosis, Lactic; Adenine; Adolescent; Antiretroviral Therapy, Highly Active; Carbamates; Diagnosis, Differential; Didanosine; Disease Progression; Drug Therapy, Combination; Fatal Outcome; Female; Furans; Guillain-Barre Syndrome; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Organophosphonates; Organophosphorus Compounds; Risk Assessment; Severity of Illness Index; Stavudine; Sulfonamides; Tenofovir | 2003 |
The long-term effects of anti-retroviral protease inhibitors on sugar transport in L6 cells.
Topics: Biological Transport; Blotting, Western; Carbamates; Cell Membrane; Cells, Cultured; Deoxyglucose; Furans; Glucose Transporter Type 1; Glucose Transporter Type 3; Glucose Transporter Type 4; HIV Protease Inhibitors; Humans; Indinavir; Insulin; Monosaccharide Transport Proteins; Muscle Proteins; Myoblasts; Nerve Tissue Proteins; Ritonavir; Saquinavir; Sulfonamides | 2003 |
Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.
Topics: Amino Acid Substitution; Antiviral Agents; Carbamates; CD4-Positive T-Lymphocytes; Cell Line; Crystallography, X-Ray; Darunavir; Drug Resistance, Multiple, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Models, Molecular; Sulfonamides; Virus Replication | 2003 |
Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients.
Topics: Adult; Anti-HIV Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mutation; Predictive Value of Tests; Reverse Transcriptase Inhibitors; Salvage Therapy; Sulfonamides; Treatment Outcome | 2003 |
Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation.
Topics: 3T3 Cells; Adipocytes; Animals; Carbamates; Cell Differentiation; Cell Line; Enzyme-Linked Immunosorbent Assay; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Mice; Mice, Inbred Strains; Nelfinavir; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides | 2003 |
Amprenavir resistance imparted by the I50V mutation in HIV-1 protease can be suppressed by the N88S mutation.
Topics: Asparagine; Carbamates; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Isoleucine; Microbial Sensitivity Tests; Mutation; Serine; Sulfonamides; Valine | 2003 |
Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation.
Topics: 3T3 Cells; Adipocytes; Animals; Blotting, Western; Carbamates; CCAAT-Enhancer-Binding Proteins; Cell Differentiation; Cell Nucleus; DNA-Binding Proteins; Furans; HIV Protease Inhibitors; Indinavir; Lamin Type A; Mice; Microscopy, Confocal; Nelfinavir; Sterol Regulatory Element Binding Protein 1; Sulfonamides; Transcription Factors | 2003 |
Potent antiviral activity of amprenavir in primary macrophages infected by human immunodeficiency virus.
Topics: Carbamates; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; In Vitro Techniques; Macrophages; Sulfonamides; Virus Replication | 2004 |
Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients.
Topics: Adult; Atazanavir Sulfate; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; HIV Seropositivity; Humans; Male; Middle Aged; Oligopeptides; Pilot Projects; Pyridines; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Outcome | 2003 |
Value of therapeutic drug monitoring in the management of patients with HIV infection undergoing haemodialysis.
Topics: Adult; AIDS-Associated Nephropathy; Antiretroviral Therapy, Highly Active; Carbamates; Drug Monitoring; Female; Furans; Humans; Lopinavir; Pyrimidinones; Renal Dialysis; Sulfonamides | 2004 |
Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates.
Topics: Carbamates; Drug Resistance, Viral; Enzyme-Linked Immunosorbent Assay; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyridines; Pyrimidinones; Pyrones; RNA, Viral; Sulfonamides | 2004 |
Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir.
Topics: Animals; Biological Availability; Biotransformation; Caco-2 Cells; Carbamates; Dogs; Furans; HIV Protease Inhibitors; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Male; Mass Spectrometry; Organophosphates; Prodrugs; Rats; Rats, Wistar; Sulfonamides | 2004 |
HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M.
Topics: Amino Acid Substitution; Carbamates; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Furans; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Microbial Sensitivity Tests; Mutation; Mutation, Missense; Phenotype; Retrospective Studies; Salvage Therapy; Sulfonamides; Viral Load | 2004 |
Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients.
Topics: Adult; Anti-Retroviral Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Mutation; Pyrimidinones; Retrospective Studies; Ritonavir; RNA, Viral; Sulfonamides | 2004 |
Long-term pharmacokinetics of amprenavir in combination with delavirdine in HIV-infected children.
Topics: Adolescent; Anti-HIV Agents; Area Under Curve; Carbamates; Child; Delavirdine; Drug Combinations; Furans; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Sulfonamides | 2004 |
The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters.
Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carbamates; Cell Line; Chromatography, Liquid; Furans; Indoles; Male; Mass Spectrometry; Mice; Mice, Knockout; Pyrroles; Receptors, N-Methyl-D-Aspartate; Sulfonamides; Tetrahydroisoquinolines; Time Factors | 2004 |
New approaches to the industrial synthesis of HIV protease inhibitors.
Topics: Carbamates; Furans; HIV Protease Inhibitors; Molecular Conformation; Molecular Structure; Organophosphates; Sulfonamides | 2004 |
Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
Topics: Adult; Amino Acid Substitution; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Male; Middle Aged; Mutation, Missense; Ritonavir; Selection, Genetic; Sulfonamides; Treatment Failure; Viral Load; Viremia | 2004 |
Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretro
Topics: Amino Acid Substitution; Carbamates; Cohort Studies; Drug Resistance, Multiple, Viral; Furans; Genes, Viral; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Multivariate Analysis; Mutation; Phenotype; Pyrimidinones; Regression Analysis; Sulfonamides | 2004 |
Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus.
Topics: Adult; Amniotic Fluid; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Maternal-Fetal Exchange; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Saquinavir; Sulfonamides | 2004 |
Effectiveness and tolerability of a once-daily amprenavir/ritonavir-containing highly active antiretroviral therapy regimen in antiretroviral-naïve patients at risk for nonadherence: 48-week results after 24 weeks of directly observed therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Directly Observed Therapy; Drug Administration Schedule; Female; Furans; HIV Infections; Humans; Male; Middle Aged; Pilot Projects; Ritonavir; Statistics, Nonparametric; Sulfonamides; Treatment Outcome; Viral Load | 2004 |
Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor.
Topics: Binding Sites; Carbamates; Darunavir; Drug Resistance, Multiple, Viral; Furans; HIV Protease Inhibitors; HIV-1; Humans; Hydrogen Bonding; Sulfonamides; Thermodynamics | 2004 |
The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells.
Topics: Algorithms; Animals; Antibiotics, Antitubercular; Antidiarrheals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Carbamates; Cell Line; Cell Membrane; Cytoplasm; Diffusion; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Furans; Kinetics; Liposomes; Loperamide; Models, Chemical; Protein Binding; Quinidine; Software; Sulfonamides; Time Factors; Xenobiotics | 2005 |
Inhibition of wild-type and mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides.
Topics: Amino Acid Substitution; Binding, Competitive; Carbamates; Chromatography, Affinity; Chromatography, Gel; Dextrans; Dimerization; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Hydrolysis; Kinetics; Protein Binding; Saquinavir; Spectrometry, Fluorescence; Substrate Specificity; Sulfonamides | 2004 |
Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.
Topics: Carbamates; Cell Line; Furans; Glucose; HIV Protease Inhibitors; Humans; Indinavir; Insulin; Insulin Receptor Substrate Proteins; Insulin Secretion; Intracellular Signaling Peptides and Proteins; Islets of Langerhans; Nelfinavir; Phosphoproteins; Phosphorylation; Ritonavir; Saquinavir; Signal Transduction; Stimulation, Chemical; Sulfonamides; Time Factors | 2004 |
Virtual screening of HIV-1 protease inhibitors against human cytomegalovirus protease using docking and molecular dynamics.
Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Binding Sites; Carbamates; Crystallography, X-Ray; Cytomegalovirus; Cytomegalovirus Infections; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Molecular Structure; Peptide Hydrolases; Sulfonamides | 2005 |
Genotype dependent QSAR for HIV-1 protease inhibition.
Topics: Carbamates; Drug Resistance, Viral; Furans; Genotype; HIV Protease; HIV Protease Inhibitors; HIV-1; Mutation; Quantitative Structure-Activity Relationship; Sulfonamides; Thermodynamics | 2005 |
Stimulation of intracellular Ca2+ elevation in neutrophils by thiol-oxidizing phenylarsine oxide.
Topics: Animals; Aorta, Abdominal; Aristolochic Acids; Arsenicals; Barium; Calcium; Calcium Signaling; Calcium-Transporting ATPases; Carbamates; Cell Membrane; Enzyme Inhibitors; Furans; Indazoles; Indoles; Male; Manganese; NADPH Oxidases; Neutrophils; Nitric Oxide; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Strontium; Sulfonamides | 2005 |
Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevi
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Calibration; Carbamates; Chromatography, Liquid; Cyclopropanes; Drug Stability; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Specimen Handling; Spectrophotometry, Ultraviolet; Sulfonamides | 2005 |
Oximinoarylsulfonamides as potent HIV protease inhibitors.
Topics: Binding Sites; Carbamates; Drug Design; Furans; HIV Protease; HIV Protease Inhibitors; Kinetics; Lopinavir; Models, Molecular; Molecular Conformation; Pyrimidinones; Ritonavir; Sulfonamides | 2005 |
Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1.
Topics: Carbamates; Chronic Disease; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Nelfinavir; Retrospective Studies; Sulfonamides; Virus Replication; Withholding Treatment | 2005 |
Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor.
Topics: Antiretroviral Therapy, Highly Active; Carbamates; Drug Resistance, Multiple, Viral; Follow-Up Studies; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Indinavir; Lopinavir; Mutation; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Treatment Failure; Viral Load | 2005 |
A long-term survival case of small cell lung cancer in an HIV-infected patient.
Topics: Alkynes; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Benzoxazines; Camptothecin; Carbamates; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Administration Schedule; Furans; HIV Infections; HIV Long-Term Survivors; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Oxazines; Ritonavir; Sulfonamides; Tomography, X-Ray Computed | 2005 |
Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients.
Topics: Adult; Atazanavir Sulfate; Carbamates; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pilot Projects; Pyridines; Saquinavir; Sulfonamides | 2005 |
Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries.
Topics: Animals; Bradykinin; Carbamates; Coronary Vessels; Down-Regulation; Furans; HIV Protease Inhibitors; Indinavir; Methionine; Muscle Contraction; Muscle, Smooth, Vascular; Myography; Nelfinavir; Nitric Oxide Synthase; Organ Culture Techniques; Ritonavir; RNA, Messenger; Saquinavir; Selenium Compounds; Sulfonamides; Superoxides; Swine; Vasomotor System | 2005 |
The steady-state Michaelis-Menten analysis of P-glycoprotein mediated transport through a confluent cell monolayer cannot predict the correct Michaelis constant Km.
Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Carbamates; Cell Line; Cell Membrane Permeability; Computer Simulation; Dogs; Furans; Humans; Loperamide; Models, Biological; Pharmacokinetics; Quinidine; Reproducibility of Results; Sulfonamides; Tetrahydroisoquinolines | 2005 |
Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal.
Topics: Adipocytes; Animals; Atazanavir Sulfate; Carbamates; Deoxyglucose; Dose-Response Relationship, Drug; Furans; Glucose; Glucose Clamp Technique; HIV Protease Inhibitors; Infusions, Intravenous; Insulin Resistance; Lopinavir; Male; Models, Animal; Muscle, Skeletal; Myocardium; Oligopeptides; Pyridines; Pyrimidinones; Rats; Ritonavir; Sulfonamides | 2005 |
A monolithic-phase based on-line extraction approach for determination of pharmaceutical components in human plasma by HPLC-MS/MS and a comparison with liquid-liquid extraction.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Calibration; Carbamates; Chromatography, High Pressure Liquid; Furans; Humans; Mass Spectrometry; Oligopeptides; Online Systems; Pharmaceutical Preparations; Pyridines; Quality Control; Reference Standards; Solutions; Sulfonamides | 2006 |
Estrogen receptor-alpha mediates gender differences in atherosclerosis induced by HIV protease inhibitors.
Topics: Animals; Atherosclerosis; Carbamates; Cholesterol; Estrogen Receptor alpha; Female; Furans; HIV Protease Inhibitors; Male; Mice; Mice, Knockout; Receptors, LDL; Sex Characteristics; Sulfonamides | 2006 |
Evolution of resistance during first-line treatment with boosted fosamprenavir is associated with baseline mutations.
Topics: Adult; Antiretroviral Therapy, Highly Active; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Male; Mutation; Organophosphates; Prodrugs; Sulfonamides | 2006 |
Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Drug Administration Schedule; Drug Interactions; Furans; HIV Infections; Humans; Oligopeptides; Organophosphates; Pyridines; Sulfonamides; Treatment Failure; Viremia | 2006 |
Intraluminal drug and formulation behavior and integration in in vitro permeability estimation: a case study with amprenavir.
Topics: Adult; Caco-2 Cells; Carbamates; Chemistry, Pharmaceutical; Excipients; Fasting; Female; Furans; Humans; In Vitro Techniques; Intestinal Absorption; Male; Permeability; Pharmaceutical Preparations; Sulfonamides | 2006 |
Determination of amprenavir total and unbound concentrations in plasma by high-performance liquid chromatography and ultrafiltration.
Topics: Area Under Curve; Carbamates; Chromatography, High Pressure Liquid; Drug Interactions; Drug Monitoring; Furans; HIV Protease Inhibitors; Humans; Protein Binding; Sulfonamides; Ultrafiltration | 2006 |
Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Topics: Aryl Hydrocarbon Hydroxylases; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Furans; HIV Protease Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Indinavir; Isoenzymes; Kinetics; Nelfinavir; Recombinant Proteins; Ritonavir; Saquinavir; Sulfonamides; Testosterone | 2006 |
Gated binding of ligands to HIV-1 protease: Brownian dynamics simulations in a coarse-grained model.
Topics: Carbamates; Computer Simulation; Enzyme Activation; Furans; HIV Protease; HIV Protease Inhibitors; Indinavir; Ligands; Models, Molecular; Mutation; Saquinavir; Sulfonamides | 2006 |
Characterization of the murine leukemia virus protease and its comparison with the human immunodeficiency virus type 1 protease.
Topics: Amino Acid Sequence; Animals; Carbamates; Escherichia coli; Furans; Gene Products, gag; HIV Protease; HIV Protease Inhibitors; Humans; Hydrogen-Ion Concentration; Leukemia Virus, Murine; Mice; Molecular Sequence Data; NIH 3T3 Cells; Oligopeptides; Peptide Hydrolases; Recombinant Proteins; Species Specificity; Sulfonamides | 2006 |
Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.
Topics: Carbamates; Codon; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Mutation; Nelfinavir; Phenotype; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides | 2006 |
Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics.
Topics: Administration, Oral; Adolescent; Adult; Carbamates; Diarrhea; Drug Administration Schedule; Drug Combinations; Esomeprazole; Female; Furans; Headache; Humans; Male; Middle Aged; Nausea; Organophosphates; Ritonavir; Sulfonamides | 2006 |
Amprenavir-induced maculopapular exanthem followed by desensitization in a patient with late-stage human immunodeficiency virus.
Topics: Adult; Carbamates; Desensitization, Immunologic; Drug Hypersensitivity; Exanthema; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides | 2006 |
Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation.
Topics: Adult; Anti-HIV Agents; Carbamates; Furans; Hepatitis C; HIV Infections; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Metabolic Clearance Rate; Middle Aged; Organophosphates; Sulfonamides; Treatment Outcome | 2006 |
[Effects of various HIV protease inhibitors on function of rat insulinoma cells].
Topics: Animals; Carbamates; Furans; HIV Protease Inhibitors; Insulin; Insulin Secretion; Insulinoma; Islets of Langerhans; Pancreatic Neoplasms; Rats; Ritonavir; Sulfonamides | 2006 |
A novel approach for in-process monitoring and managing cross-contamination in a high-throughput high-performance liquid chromatography assay with tandem mass spectrometric detection.
Topics: Biomarkers; Carbamates; Chemistry Techniques, Analytical; Chromatography, High Pressure Liquid; Drug Contamination; Furans; Humans; Lopinavir; Pyrimidinones; Quality Control; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides; Tandem Mass Spectrometry | 2006 |
Insights into amprenavir resistance in E35D HIV-1 protease mutation from molecular dynamics and binding free-energy calculations.
Topics: Amino Acid Substitution; Aspartic Acid; Carbamates; Drug Resistance, Viral; Furans; Glutamic Acid; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Protein Binding; Sulfonamides; Thermodynamics | 2007 |
New, potent P1/P2-morpholinone-based HIV-protease inhibitors.
Topics: Carbamates; Furans; HIV Protease Inhibitors; Humans; Molecular Mimicry; Morpholines; Peptides, Cyclic; Structure-Activity Relationship; Sulfonamides | 2006 |
Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir
Topics: Atazanavir Sulfate; Calibration; Carbamates; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Stability; Fluorescence; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Pyridines; Pyrimidinones; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides; Ultraviolet Rays | 2007 |
An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Spectrophotometry, Ultraviolet; Sulfonamides | 2007 |
A combined empirical and mechanistic codon model.
Topics: Amino Acid Substitution; Animals; Anti-HIV Agents; Carbamates; Chloroplasts; Codon; Drug Resistance, Viral; Evolution, Molecular; Furans; Genes, Mitochondrial; Genes, Viral; HIV Infections; HIV Protease; HIV-1; Humans; Markov Chains; Models, Genetic; Models, Statistical; Mutation; Selection, Genetic; Sulfonamides | 2007 |
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
Topics: Amino Acid Sequence; Carbamates; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; HIV-2; Humans; Indinavir; Molecular Sequence Data; Mutation; Nelfinavir; Polymorphism, Genetic; Pyridines; Pyrones; Sulfonamides | 2007 |
P-Glycoprotein (P-gp) expressed in a confluent monolayer of hMDR1-MDCKII cells has more than one efflux pathway with cooperative binding sites.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Biological Transport, Active; Carbamates; Cell Line; Cell Membrane Permeability; Dogs; Furans; Humans; Loperamide; Protein Binding; Quinidine; Signal Transduction; Substrate Specificity; Sulfonamides | 2006 |
In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: illustration of intraluminal supersaturation.
Topics: Alkaline Phosphatase; Biological Transport; Caco-2 Cells; Carbamates; Chromatography, High Pressure Liquid; Drug Stability; Furans; HIV Protease Inhibitors; Humans; Intestinal Absorption; Intestinal Secretions; Organophosphates; Permeability; Phosphates; Phosphorylation; Prodrugs; Solubility; Sulfonamides | 2007 |
High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Stability; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Molecular Structure; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Pyrones; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfonamides; Time Factors | 2007 |
Ligand configurational entropy and protein binding.
Topics: Algorithms; Anti-HIV Agents; Carbamates; Drug Design; Entropy; Furans; HIV Protease; Ligands; Models, Chemical; Models, Statistical; Molecular Conformation; Protein Binding; Protein Conformation; Proteins; Sulfonamides; Thermodynamics | 2007 |
Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks.
Topics: Administration, Oral; Adult; Aged; Anti-HIV Agents; Carbamates; Female; Furans; Humans; Male; Middle Aged; Models, Biological; Sulfonamides | 2007 |
Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance.
Topics: Binding Sites; Carbamates; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; Models, Molecular; Mutation; Protein Binding; Protein Conformation; Sulfonamides; Thermodynamics | 2007 |
Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients.
Topics: Carbamates; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; Sulfonamides; Treatment Failure; Viral Load | 2007 |
Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir.
Topics: Adenine; Adult; Age Factors; Analysis of Variance; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Weight; Carbamates; Creatinine; Didanosine; Drug Interactions; Female; Furans; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Linear Models; Male; Middle Aged; Organophosphonates; Sulfonamides; Tenofovir; Time Factors | 2007 |
Development and evaluation of an immunoassay for the monitoring of the anti-HIV drug amprenavir.
Topics: Adult; Animals; Anti-HIV Agents; Antibodies; Carbamates; Chromatography, High Pressure Liquid; Cross Reactions; Drug Monitoring; Enzyme-Linked Immunosorbent Assay; Furans; Humans; Immune Sera; Molecular Structure; Organophosphates; Ovalbumin; Rabbits; Reproducibility of Results; Serum Albumin, Bovine; Sulfonamides; Vaccination | 2007 |
Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Attention; Bilirubin; Carbamates; Chromatography, High Pressure Liquid; Female; Furans; HIV Infections; Humans; Liver Diseases; Male; Middle Aged; Organophosphates; Plasma; Ritonavir; Sulfonamides; Time Factors | 2007 |
Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels.
Topics: Adult; Antiviral Agents; Carbamates; Chromatography, High Pressure Liquid; Furans; Hepacivirus; Hepatitis B virus; Hepatitis C, Chronic; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Liver Cirrhosis; Middle Aged; Ritonavir; Sulfonamides; Treatment Outcome | 2007 |
Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence.
Topics: Androgens; Animals; Apoptosis; Calpain; Carbamates; Cell Line, Tumor; Dipeptides; Enzyme Activation; Furans; Humans; Ionomycin; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Receptors, Androgen; Sulfonamides; Transcriptional Activation; Transfection; Transplantation, Heterologous | 2007 |
Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamates; Cell Line; Cell Membrane; Digoxin; Dogs; Furans; Kinetics; Loperamide; Quinidine; Sulfonamides | 2008 |
[Pharmacokinetics of amprenavir in HIV-1 patients with renal insufficiency].
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Carbamates; Female; Furans; Humans; Kidney Function Tests; Male; Middle Aged; Renal Insufficiency; Sulfonamides | 2007 |
In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Boron Compounds; Carbamates; Carbon Radioisotopes; Cyclosporine; Drug Interactions; Fluorescent Dyes; Furans; Humans; LLC-PK1 Cells; Positron-Emission Tomography; Quinidine; Quinine; Rats; Sulfonamides; Swine; Verapamil | 2008 |
Different evidence of key amprenavir resistance mutations on the efficacy of darunavir.
Topics: Carbamates; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Failure; Treatment Outcome | 2008 |
Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Bayes Theorem; Benzoxazines; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; France; Furans; HIV Infections; Humans; Male; Models, Biological; Nevirapine; Organophosphates; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides | 2008 |
Determination of abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine concentration in human plasma by MALDI-TOF/TOF.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Monitoring; Feasibility Studies; Furans; Humans; Molecular Structure; Nevirapine; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Spectrophotometry, Ultraviolet; Stavudine; Sulfonamides | 2008 |
[Plasma levels following the switch from amprenavir to fosamprenavir in HIV-infected patients under antiretroviral treatment with lopinavir/ritonavir].
Topics: Adult; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Ritonavir; Sulfonamides | 2008 |
HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants.
Topics: Algorithms; Carbamates; Crystallography, X-Ray; Darunavir; Drug Design; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Kinetics; Models, Molecular; Structure-Activity Relationship; Sulfonamides | 2008 |
Same patient, new stone composition: amprenavir urinary stone.
Topics: Adult; Anti-HIV Agents; Carbamates; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir; Sulfonamides; Tomography, X-Ray Computed; Urinary Calculi | 2008 |
A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4.
Topics: Animals; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Furans; Gene Expression; Gene Expression Regulation; HIV Protease Inhibitors; Humans; Intestine, Small; Ketoconazole; Liver; Male; Mice; Mice, Knockout; Mice, Transgenic; Microsomes, Liver; Models, Animal; Nelfinavir; Pregnane X Receptor; Pregnenolone Carbonitrile; Receptors, Steroid; Rifampin; Saquinavir; Sex Characteristics; Sulfonamides | 2008 |
Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir.
Topics: Binding Sites; Carbamates; Darunavir; Furans; HIV Protease Inhibitors; HIV-1; Kinetics; Models, Molecular; Molecular Structure; Sulfonamides | 2008 |
Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
Topics: Atazanavir Sulfate; Binding Sites; Binding, Competitive; Calorimetry, Differential Scanning; Carbamates; Crystallography, X-Ray; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Kinetics; Lopinavir; Models, Molecular; Molecular Structure; Mutation; Nelfinavir; Oligopeptides; Pepsin A; Protein Binding; Protein Structure, Tertiary; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Saquinavir; Sulfonamides | 2009 |
Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Solid Phase Extraction; Sulfonamides | 2009 |
PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.
Topics: Carbamates; Catalytic Domain; Cells, Cultured; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Leukocytes, Mononuclear; Models, Molecular; Mutagenesis, Site-Directed; Mutation, Missense; Protein Structure, Tertiary; Sulfonamides | 2008 |
Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.
Topics: Amino Acid Sequence; Carbamates; Cell Line; Drug Resistance, Viral; Furans; gag Gene Products, Human Immunodeficiency Virus; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation, Missense; Sulfonamides; Virus Replication | 2009 |
Resistance mechanism revealed by crystal structures of unliganded nelfinavir-resistant HIV-1 protease non-active site mutants N88D and N88S.
Topics: Asparagine; Aspartic Acid; Carbamates; Catalytic Domain; Crystallography, X-Ray; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Hydrogen Bonding; Mutation; Nelfinavir; Sulfonamides | 2009 |
HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells.
Topics: Animals; Apoptosis; Carbamates; Cell Line; Cell Membrane Permeability; Endoplasmic Reticulum; Furans; HIV Infections; HIV Protease Inhibitors; Intestinal Mucosa; Lopinavir; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Pyrimidinones; Ritonavir; Stress, Physiological; Sulfonamides; Transcription Factor CHOP | 2010 |
Multiple effects of amprenavir against Candida albicans.
Topics: Aspartic Acid Endopeptidases; Biofilms; Blood; Candida albicans; Candidiasis; Carbamates; Culture Media; Fungal Proteins; Fungemia; Furans; HIV Protease Inhibitors; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Sulfonamides | 2010 |
Effects of the V82A and I54V mutations on the dynamics and ligand binding properties of HIV-1 protease.
Topics: Amino Acid Substitution; Binding Sites; Carbamates; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; Ligands; Models, Molecular; Mutation; Protein Structure, Tertiary; Ritonavir; Sulfonamides | 2010 |
Identification of proteasome gene regulation in a rat model for HIV protease inhibitor-induced hyperlipidemia.
Topics: Animals; Atazanavir Sulfate; Carbamates; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Furans; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; HIV Protease Inhibitors; Hyperlipidemias; Male; Oligonucleotide Array Sequence Analysis; Oligopeptides; Proteasome Endopeptidase Complex; Pyridines; Rats; Rats, Sprague-Dawley; Ritonavir; Sulfonamides | 2010 |
Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes.
Topics: Animals; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Carbamates; Cells, Cultured; Fluoresceins; Furans; Hepatocytes; HIV Protease Inhibitors; Humans; Indinavir; Liver; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Nelfinavir; Rats; Rats, Wistar; Ritonavir; Saquinavir; Sulfonamides | 2010 |
Effect of the HIV protease inhibitor amprenavir on the growth and differentiation of primary gingival epithelium.
Topics: 3T3 Cells; Animals; Antiretroviral Therapy, Highly Active; Carbamates; Cell Differentiation; Cell Proliferation; Cells, Cultured; Coculture Techniques; Epithelium; Fibroblasts; Furans; Gingiva; HIV Protease Inhibitors; Humans; Keratinocytes; Mice; Organ Specificity; Sulfonamides | 2010 |
Genotypic and phenotypic evolution of HIV type-1 protease during in vitro sequential or concomitant combination of atazanavir and amprenavir.
Topics: Atazanavir Sulfate; Carbamates; Cell Line; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Evolution, Molecular; Furans; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Phenotype; Pyridines; Recombination, Genetic; Sulfonamides; Treatment Failure | 2010 |
Validation of a differential in situ perfusion method with mesenteric blood sampling in rats for intestinal drug interaction profiling.
Topics: Adrenergic beta-Antagonists; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamates; Drug Interactions; Furans; Intestinal Absorption; Ketoconazole; Male; Perfusion; Polyethylene Glycols; Rats; Rats, Wistar; Splanchnic Circulation; Sulfonamides; Verapamil; Vitamin E | 2010 |
Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.
Topics: Adult; Anti-HIV Agents; Carbamates; Case-Control Studies; Cohort Studies; Confidence Intervals; Dideoxynucleosides; Female; France; Furans; HIV Infections; Hospitals, Isolation; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Organophosphates; Regression Analysis; Risk; Ritonavir; Sulfonamides | 2010 |
Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters.
Topics: Amino Acid Substitution; Carbamates; Crystallography, X-Ray; Dimerization; Drug Resistance, Multiple, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Hydrophobic and Hydrophilic Interactions; Kinetics; Molecular Conformation; Mutation; Protein Binding; Protein Interaction Domains and Motifs; Saquinavir; Sulfonamides | 2010 |
HIV protease inhibitors elicit volume-sensitive Cl- current in cardiac myocytes via mitochondrial ROS.
Topics: Action Potentials; Animals; Carbamates; Chloride Channels; Furans; HIV Integrase Inhibitors; HIV Protease Inhibitors; Ion Channel Gating; Lopinavir; Membrane Potential, Mitochondrial; Mitochondria; Myocytes, Cardiac; Nelfinavir; Pyrimidinones; Pyrrolidinones; Rabbits; Raltegravir Potassium; Reactive Oxygen Species; Ritonavir; Sulfonamides; Time Factors | 2010 |
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
Topics: Antiviral Agents; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Mutation; Pyrimidinones; Sulfonamides | 2010 |
Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors.
Topics: Carbamates; Crystallography, X-Ray; Darunavir; Dimerization; Drug Design; Drug Resistance, Multiple, Viral; Furans; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Proteins; Structure-Activity Relationship; Sulfonamides | 2010 |
Effects of HIV protease inhibitors on progression of monocrotaline- and hypoxia-induced pulmonary hypertension in rats.
Topics: Animals; Animals, Newborn; Antiretroviral Therapy, Highly Active; Antiviral Agents; Blood Pressure; Carbamates; Cell Division; Furans; Hemodynamics; HIV Protease Inhibitors; Hypertension, Pulmonary; Hypoxia; Male; Monocrotaline; Nelfinavir; Pulmonary Artery; Rats; Rats, Wistar; Ritonavir; Sulfonamides | 2010 |
Simultaneous bioanalysis of a phosphate prodrug and its parent compound using a multiplexed LC-MS method.
Topics: Animals; Carbamates; Chromatography, Liquid; Drug Stability; Furans; Hydrophobic and Hydrophilic Interactions; Male; Mass Spectrometry; Organophosphates; Phosphates; Prodrugs; Rats; Rats, Sprague-Dawley; Sulfonamides; Time Factors | 2010 |
Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants.
Topics: Animals; Carbamates; Cell Line; Chlorocebus aethiops; COS Cells; Drug Resistance, Viral; Furans; HIV Protease Inhibitors; HIV-1; Humans; Pyrans; Sulfonamides | 2011 |
Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis.
Topics: Animals; Antiviral Agents; Autoradiography; beta-Galactosidase; Carbamates; Cell Line, Tumor; Cell Survival; Chickens; Dihydroorotate Dehydrogenase; DNA Primers; Furans; Humans; Indoles; Lamivudine; Mammals; Nevirapine; Oxadiazoles; Oxidoreductases Acting on CH-CH Group Donors; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Species Specificity; Sulfonamides; Time Factors; Virus Replication; Viruses | 2011 |
In vitro activity of antiretroviral drugs against Plasmodium falciparum.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Antimalarials; Benzoxazines; Carbamates; Cyclopropanes; Darunavir; Furans; Lopinavir; Nelfinavir; Nevirapine; Plasmodium falciparum; Pyridines; Pyrones; Ritonavir; Saquinavir; Sulfonamides | 2011 |
Elucidating the energetics of entropically driven protein-ligand association: calculations of absolute binding free energy and entropy.
Topics: Carbamates; Entropy; Furans; HIV Protease; HIV-1; Ligands; Molecular Dynamics Simulation; Nelfinavir; Protease Inhibitors; Protein Binding; Sulfonamides | 2011 |
Structural and biochemical characterization of the inhibitor complexes of xenotropic murine leukemia virus-related virus protease.
Topics: Animals; Binding Sites; Carbamates; Crystallography, X-Ray; Dimerization; Furans; Mice; Models, Molecular; Pepstatins; Peptide Hydrolases; Protease Inhibitors; Protein Binding; Protein Conformation; Sulfonamides; Xenotropic murine leukemia virus-related virus | 2011 |
Fitting the elementary rate constants of the P-gp transporter network in the hMDR1-MDCK confluent cell monolayer using a particle swarm algorithm.
Topics: Adenosine Triphosphate; Algorithms; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Carbamates; Cell Line; Digoxin; Dogs; Furans; Humans; Hydrolysis; Kinetics; Loperamide; Sulfonamides | 2011 |
Factors associated with insulin resistance among children and adolescents perinatally infected with HIV-1 in the pediatric HIV/AIDS cohort study.
Topics: Adolescent; Body Mass Index; Carbamates; CD4 Lymphocyte Count; Child; Cohort Studies; Cross-Sectional Studies; Female; Furans; Glucose Intolerance; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Insulin Resistance; Male; Obesity; Prevalence; Prospective Studies; Puberty; Sulfonamides; United States | 2011 |
Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions.
Topics: Antiviral Agents; Atazanavir Sulfate; Carbamates; Carboxylic Ester Hydrolases; Drug Interactions; Furans; Humans; Kinetics; Models, Molecular; Nelfinavir; Oligopeptides; Protease Inhibitors; Pyridines; Quantitative Structure-Activity Relationship; Ritonavir; Saquinavir; Sulfonamides | 2012 |
Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors.
Topics: Amino Acid Sequence; Binding Sites; Carbamates; Crystallography, X-Ray; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; HIV-2; Kinetics; Saquinavir; Sulfonamides | 2012 |
Therapeutic amprenavir concentrations in cerebrospinal fluid.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD4-Positive T-Lymphocytes; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Male; Middle Aged; Sulfonamides; Tandem Mass Spectrometry | 2012 |
Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.
Topics: Carbamates; Catalytic Domain; Cell Line; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Models, Molecular; Sulfonamides | 2012 |
Effect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibility.
Topics: Amino Acid Substitution; Atazanavir Sulfate; Carbamates; Drug Resistance, Viral; Furans; HEK293 Cells; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Oligopeptides; Open Reading Frames; Plasmids; Polymorphism, Genetic; Pyridines; Sulfonamides; Transfection | 2012 |
Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir.
Topics: Amino Acids; Carbamates; Catalytic Domain; Computer Simulation; Drug Resistance; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Models, Molecular; Mutation; Protein Binding; Sulfonamides; Thermodynamics | 2012 |
Nanoparticle-mediated targeted delivery of antiretrovirals to the brain.
Topics: Anti-HIV Agents; Blood-Brain Barrier; Brain; Cadmium Compounds; Carbamates; Cell Survival; Cells, Cultured; Electric Impedance; Endothelial Cells; Furans; Gene Expression; HIV Core Protein p24; HIV Long Terminal Repeat; HIV-1; Humans; Leukocytes, Mononuclear; Microvessels; Nanoconjugates; Particle Size; Primary Cell Culture; Quantum Dots; Selenium Compounds; Sulfates; Sulfonamides; Transferrin; Zinc Sulfate | 2012 |
Role of FAP48 in HIV-associated lipodystrophy.
Topics: Adaptor Proteins, Signal Transducing; Adipocytes; Alkynes; Animals; Antiretroviral Therapy, Highly Active; Benzoxazines; Calcineurin; Carbamates; Cell Differentiation; Cell Line; Cyclopropanes; Furans; Gene Expression; Glucocorticoids; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Indinavir; Mice; Saquinavir; Signal Transduction; Stavudine; Sulfonamides; Transfection | 2012 |
Molecular and enzymatic characterization of XMRV protease by a cell-free proteolytic analysis.
Topics: Animals; bcl-2-Associated X Protein; Carbamates; Cell Line, Tumor; Cell-Free System; Furans; HIV Protease Inhibitors; Humans; Mice; Peptide Hydrolases; Proteolysis; PTEN Phosphohydrolase; Substrate Specificity; Sulfonamides; Viral Proteins; Xenotropic murine leukemia virus-related virus | 2012 |
NMR study of xenotropic murine leukemia virus-related virus protease in a complex with amprenavir.
Topics: Carbamates; Drug Discovery; Furans; HIV Protease Inhibitors; HIV-1; Nuclear Magnetic Resonance, Biomolecular; Peptide Hydrolases; Protein Structure, Secondary; Sulfonamides; Viral Nonstructural Proteins; Xenotropic murine leukemia virus-related virus | 2012 |
Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Carbamates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Activation; Furans; HIV Protease Inhibitors; Humans; Liver Neoplasms; Male; Matrix Metalloproteinase 2; Mice; Mice, Nude; Neoplasm Invasiveness; Proto-Oncogene Proteins c-akt; Sulfonamides; Xenograft Model Antitumor Assays | 2013 |
Interaction between HIV protease inhibitors (PIs) and hepatic transporters in sandwich cultured human hepatocytes: implication for PI-based DDIs.
Topics: Carbamates; Cells, Cultured; Drug Interactions; Furans; Hepatocytes; HIV Protease Inhibitors; Humans; Lopinavir; Nelfinavir; Organic Anion Transporters; Ritonavir; Sulfonamides | 2013 |
Structural and thermodynamic basis of amprenavir/darunavir and atazanavir resistance in HIV-1 protease with mutations at residue 50.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Crystallography, X-Ray; Darunavir; Drug Resistance, Viral; Furans; HIV Protease; HIV-1; Humans; Kinetics; Models, Molecular; Mutant Proteins; Mutation, Missense; Oligopeptides; Point Mutation; Protein Binding; Protein Conformation; Pyridines; Sulfonamides; Thermodynamics | 2013 |
GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
Topics: Amino Acid Sequence; Atazanavir Sulfate; Binding Sites; Carbamates; Cell Line, Tumor; Darunavir; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Lopinavir; Molecular Docking Simulation; Molecular Sequence Data; Oligopeptides; Protein Binding; Pyridines; Ritonavir; Structure-Activity Relationship; Sulfonamides; T-Lymphocytes; Virus Replication | 2013 |
Pregnane X receptor mediates dyslipidemia induced by the HIV protease inhibitor amprenavir in mice.
Topics: Animals; Binding Sites; Carbamates; Cell Line; Dyslipidemias; Furans; Gene Expression; HIV Protease Inhibitors; Humans; Lipids; Mice; Mice, Inbred C57BL; Mice, Knockout; Molecular Docking Simulation; Pregnane X Receptor; Receptors, Steroid; Sulfonamides | 2013 |
Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran.
Topics: Binding Sites; Calorimetry, Differential Scanning; Carbamates; Crystallization; Darunavir; Drug Resistance, Multiple; Drug Resistance, Viral; Escherichia coli; Furans; Genes, Synthetic; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Models, Molecular; Mutation; Pyrrolidinones; Structure-Activity Relationship; Sulfonamides | 2013 |
NIMROD: a program for inference via a normal approximation of the posterior in models with random effects based on ordinary differential equations.
Topics: Algorithms; Anti-HIV Agents; Bayes Theorem; Carbamates; Clinical Trials as Topic; Drug Monitoring; Furans; HIV Infections; Humans; Likelihood Functions; Models, Statistical; Reproducibility of Results; Software; Sulfonamides | 2013 |
Joint X-ray/neutron crystallographic study of HIV-1 protease with clinical inhibitor amprenavir: insights for drug design.
Topics: Carbamates; Catalytic Domain; Crystallography, X-Ray; Drug Design; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hydrogen Bonding; Models, Molecular; Molecular Structure; Neutron Diffraction; Protein Binding; Protein Structure, Tertiary; Sulfonamides | 2013 |
Intestinal first-pass metabolism by cytochrome p450 and not p-glycoprotein is the major barrier to amprenavir absorption.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Biological Transport; Carbamates; Cytochrome P-450 CYP3A; Furans; Intestinal Absorption; Intestinal Mucosa; Intestines; Male; Mice; Permeability; Sulfonamides | 2013 |
A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
Topics: Anti-HIV Agents; Carbamates; Cluster Analysis; Darunavir; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Hydrogen Bonding; Indinavir; Molecular Dynamics Simulation; Mutation; Protein Conformation; Saquinavir; Sulfonamides; Thermodynamics | 2013 |
In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia.
Topics: Antirheumatic Agents; Atazanavir Sulfate; Bilirubin; Carbamates; Cyclosporine; Furans; Glucuronosyltransferase; HIV Protease Inhibitors; Hyperbilirubinemia; In Vitro Techniques; Indinavir; Liver-Specific Organic Anion Transporter 1; Oligopeptides; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Pyridines; Rifampin; Rifamycins; Saquinavir; Solute Carrier Organic Anion Transporter Family Member 1B3; Sulfonamides | 2014 |
Transport inhibition of digoxin using several common P-gp expressing cell lines is not necessarily reporting only on inhibitor binding to P-gp.
Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Carbamates; Cell Membrane Permeability; Cyclosporine; Digoxin; Dogs; Furans; Gene Expression; Humans; Ketoconazole; Kinetics; Loperamide; Madin Darby Canine Kidney Cells; Protein Binding; Quinidine; Sulfonamides; Tetrahydroisoquinolines; Vinblastine | 2013 |
Revealing origin of decrease in potency of darunavir and amprenavir against HIV-2 relative to HIV-1 protease by molecular dynamics simulations.
Topics: Carbamates; Catalytic Domain; Darunavir; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; HIV-2; Hydrogen Bonding; Molecular Dynamics Simulation; Protein Binding; Protein Structure, Secondary; Sulfonamides; Thermodynamics | 2014 |
Decoding the anti-Trypanosoma cruzi action of HIV peptidase inhibitors using epimastigotes as a model.
Topics: Animals; Anti-HIV Agents; Aspartic Acid Proteases; Carbamates; Furans; Host-Parasite Interactions; Indinavir; Insect Vectors; Lopinavir; Microscopy, Electron, Transmission; Nelfinavir; Protease Inhibitors; Ritonavir; Saquinavir; Sulfonamides; Trypanocidal Agents; Trypanosoma cruzi | 2014 |
A novel tricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor, GRL-0739, effectively inhibits the replication of multidrug-resistant HIV-1 variants and has a desirable central nervous system penetration property in vitro.
Topics: Blood-Brain Barrier; Carbamates; Darunavir; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Furans; HIV Protease Inhibitors; HIV-1; Humans; Sulfonamides; Virus Replication | 2015 |
Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir.
Topics: Binding Sites; Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Molecular Dynamics Simulation; Mutation; Protein Binding; Protein Structure, Tertiary; Sulfonamides; Thermodynamics | 2015 |
Understanding the basis of I50V-induced affinity decrease in HIV-1 protease via molecular dynamics simulations using polarized force field.
Topics: Carbamates; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Molecular Dynamics Simulation; Point Mutation; Protein Binding; Sulfonamides | 2015 |
Brief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Sulfonamides; Viral Load | 2015 |
Fluorogenic Assay for Inhibitors of HIV-1 Protease with Sub-picomolar Affinity.
Topics: Carbamates; Darunavir; Fluorescence; Fluorescent Dyes; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Kinetics; Pyridines; Pyrones; Sulfonamides | 2015 |
A Comparative Insight into Amprenavir Resistance of Mutations V32I, G48V, I50V, I54V, and I84V in HIV-1 Protease Based on Thermodynamic Integration and MM-PBSA Methods.
Topics: Anti-HIV Agents; Carbamates; Drug Resistance, Viral; Furans; HIV-1; Humans; Hydrogen Bonding; Molecular Dynamics Simulation; Mutation; Sulfonamides; Thermodynamics; Viral Proteins | 2015 |
HIV protease inhibitors disrupt astrocytic glutamate transporter function and neurobehavioral performance.
Topics: Amino Acid Transport System X-AG; Animals; Astrocytes; Brain Chemistry; Carbamates; Cell Survival; Cells, Cultured; Female; Furans; Gene Expression Profiling; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Mice, Transgenic; Nervous System Diseases; Neurologic Examination; Sulfonamides | 2016 |
Colorectal delivery and retention of PEG-Amprenavir-Bac7 nanoconjugates--proof of concept for HIV mucosal pre-exposure prophylaxis.
Topics: Administration, Rectal; Animals; Caco-2 Cells; Carbamates; Cell-Penetrating Peptides; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Intestinal Mucosa; Male; Mice; Mice, Inbred Strains; Nanoconjugates; Peptides, Cyclic; Polyethylene Glycols; Pre-Exposure Prophylaxis; Sulfonamides | 2016 |
Computational Prediction of HIV-1 Resistance to Protease Inhibitors.
Topics: Amino Acid Sequence; Carbamates; Computational Biology; Darunavir; Drug Evaluation, Preclinical; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Models, Molecular; Mutation; Protein Multimerization; Protein Structure, Quaternary; Sulfonamides | 2016 |
A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.
Topics: Animals; Blood-Brain Barrier; Carbamates; Cell Line; Central Nervous System; Crystallography, X-Ray; Darunavir; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Viral; Ethylamines; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Peptides; Rats; Structure-Activity Relationship; Sulfonamides; Virus Replication | 2016 |
Extrapolation of Elementary Rate Constants of P-glycoprotein-Mediated Transport from MDCKII-hMDR1-NKI to Caco-2 Cells.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Carbamates; Cell Culture Techniques; Cell Membrane; Cell Membrane Permeability; Digoxin; Dogs; Furans; Humans; Kinetics; Loperamide; Madin Darby Canine Kidney Cells; Models, Biological; Quinidine; Sulfonamides | 2017 |
Repositioning of amprenavir as a novel extracellular signal-regulated kinase-2 inhibitor and apoptosis inducer in MCF-7 human breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bcl-2-Like Protein 11; Breast Neoplasms; Carbamates; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Repositioning; Female; Furans; HIV Protease Inhibitors; Humans; Male; MCF-7 Cells; Mice; Mice, Inbred C57BL; Mice, Nude; Mitogen-Activated Protein Kinase 1; Molecular Docking Simulation; Molecular Dynamics Simulation; Phosphorylation; RNA Interference; RNA, Small Interfering; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2017 |
Effects of Amprenavir on HIV-1 Maturation, Production and Infectivity Following Drug Withdrawal in Chronically-Infected Monocytes/Macrophages.
Topics: Carbamates; Cells, Cultured; Furans; HIV Protease Inhibitors; HIV-1; Humans; Macrophages; Monocytes; Sulfonamides; Virus Replication | 2017 |
Analysis of the HIV-2 protease's adaptation to various ligands: characterization of backbone asymmetry using a structural alphabet.
Topics: Carbamates; Crystallography, X-Ray; Darunavir; Enzyme Inhibitors; Furans; HIV Protease; Protein Binding; Protein Conformation; Protein Subunits; Sulfonamides | 2018 |
Exploring molecular mechanism of allosteric inhibitor to relieve drug resistance of multiple mutations in HIV-1 protease by enhanced conformational sampling.
Topics: Allosteric Regulation; Binding Sites; Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Hydrogen Bonding; Molecular Dynamics Simulation; Mutation; Protein Binding; Protein Conformation; Sulfonamides; Thermodynamics | 2018 |
Aspartic peptidase of
Topics: Antifungal Agents; Aspartic Acid Proteases; Carbamates; Dose-Response Relationship, Drug; Furans; HIV Protease Inhibitors; Humans; Lopinavir; Macrophages; Microbial Sensitivity Tests; Molecular Structure; Phialophora; Ritonavir; Structure-Activity Relationship; Sulfonamides | 2020 |
Revealing the binding and drug resistance mechanism of amprenavir, indinavir, ritonavir, and nelfinavir complexed with HIV-1 protease due to double mutations G48T/L89M by molecular dynamics simulations and free energy analyses.
Topics: Anti-HIV Agents; Carbamates; Drug Resistance; Furans; HIV Protease; Indinavir; Molecular Conformation; Molecular Dynamics Simulation; Mutation; Nelfinavir; Protein Binding; Ritonavir; Sulfonamides | 2020 |
Interactive molecular dynamics in virtual reality for accurate flexible protein-ligand docking.
Topics: Benzamidines; Binding Sites; Carbamates; Furans; HIV Protease; Ligands; Molecular Dynamics Simulation; Neuraminidase; Oseltamivir; Protein Binding; Sulfonamides; Trypsin; Virtual Reality; Zanamivir | 2020 |
The HIV - 1 protease inhibitor Amprenavir targets Leishmania donovani topoisomerase I and induces oxidative stress-mediated programmed cell death.
Topics: Antiprotozoal Agents; Apoptosis; Carbamates; DNA Topoisomerases, Type I; Furans; HIV Protease Inhibitors; Leishmania donovani; Oxidative Stress; Protozoan Proteins; Sulfonamides | 2021 |
Insights into effect of the Asp25/Asp25' protonation states on binding of inhibitors Amprenavir and MKP97 to HIV-1 protease using molecular dynamics simulations and MM-GBSA calculations.
Topics: Aspartic Acid; Benzothiazoles; Carbamates; Furans; HIV Protease; HIV Protease Inhibitors; Molecular Dynamics Simulation; Protein Stability; Protons; Sulfonamides | 2021 |